

Lung cancer,

Program	PRELIMINARY diagnosis and prediction.	
Wednesday, Septen		
09:30 - 10:00	Arrival, coffee	
10:00 - 10:15 15	Welcome and introduction SN	
10:15 - 11:00 45	Immunohistochemical principles: The technical test approach – pre-analytical phase I	
11:05 - 11:50 45	Immunohistochemical principles: The technical test approach – pre-analytical phase II ON	
12:00 – 12:45 45	Immunohistochemical principles: The technical test approach - analytical phase I MB	
12:45 - 13: 30 45	Lunch	
13:30 - 14:15 45	Immunohistochemical principles: The technical test approach - analytical phase If SYCEHI	
14:20 4/15:05 45	Immunonictochemical principles:	18.
Region Syddanmark	The technical test approach - post-analytical phase I	
15:05 – 15.25 20	Coffee	
15:25 / G6:10 S LIII 45) 8	Immunohistochemical principles: The technical test approach post-analytical phase II	
16:15 - 17:00 45	Immunohistochemical classification of breast tumours	
17.00 - 19.00	Social arrangement (optional) – Keglespil (<u>Skittles</u>)	

	· 	
08:15 - 09:00 45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45 45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10 20	Coffee	
Henrik Hager	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
Dept. of Clinical Pathology	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 Yejle Hospital 30	Optimization of antibodies, selection, protocols and	CN




Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th



	Optimization of antibodies, selection, protocols and controls – breast tumours NORDCAN Associate	SN	
09:00 - 09:45 45	Immunohistochemical classification of the unknown primary tumour – part I	MV	25.3.2019
09:50 - 10:10 20	Coffee		
	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN	
	Immunohistochemical classification of the unknown primary tumour – part II	MV	
	Optimization of antibodies, selection, protocols and		




Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th



	_			
08:15 - 09:00	Female 45	Optimization of antibodies, selection, protocols and	SN	
	Males	controls – breast tumours NORDCAN, Associat		dic Cancer Registries
09:00 - 09:45	45	Immunohistochemical classification of the	MV	25.3.2019
		unknown primary tumour – part I		
09:50 - 10:10	20	Coffee		W m } m
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN	
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV	45
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CNI	




Lung cancer,

diagnosis and prediction.



Program





Lung cancer,

diagnosis and prediction.

Optimization of antibodies, selection, protocols and

Program

11:35 - 12:05

30

LWAdge Cayr Et Pt Entre 20th

09:30 -10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemical principles	NOOus
		The technical test approach - pre-analytical phase 11	OIN
12:00 - 12:45	45	Immunohistochemical principles:	МВ
		bronchus	leuro-endocrir
12:45 - 13:30	45	Lunch Secondary Basal cell Basement membrane	w11
13:30 - 14:15	45	Immunohistochemical principles:	MB
		Tertiary technical test approach - analytical phase II Respiratory bronchiole	
14:20 - 15:05	45	Immunohistochemical principles:	SN
15.05 15.05		The technical test approach - post-analytical phase I	
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochemical principles:	SN
16 15 17 00	4-	The technical test approach - post-analytical phase II	
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL
17.00 - 19.00		Social arrangement (optional) – Keglespilo (Skittles)	eolar
		Chiated Cell	it .
Thursday, Septe	embe	r 2 Alveolus	Alveolus
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	
		controls - breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the	MV
		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee O	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
		controlsing reason of the controls of the ce	lls
10:45 - 11:30	45	Immunohistochemical classification of the	MV
		unknown primary i թագիթարև ութարարի արգութարի և արգութարի և հարարարարի արգութարի արգութարի և արգութարի և արգութ	1*1 V





Program

Wednesday, September 20th 09:30 - 10:00 Arrival, co

09.30 10.00		Allivai, C
10:00 - 10:15	15	Welcome
10:15 - 11:00	45	Immunoh
		The techr
11:05 - 11:50	45	Immunoh
		The techr
12:00 - 12:45	45	Immunoh
		The techr
12:45 - 13:30	45	Lunch
13:30 - 14:15	45	Immunoh
		The techr
14:20 - 15:05	45	Immunoh
		The techr
15:05 - 15.25		Coffee
15:25 - 16:10	45	
		The techr
16:15 - 17:00	45	Immunoh
		tumours
17.00 - 19.00		Social arr
Thursday, Sept	embe	er 21 st
08:15 - 09:00	45	Optimizat
		controls -

Thursday, Sept	embe	er 21 st
08:15 - 09:00	45	Optimizat
		controls -
09:00 - 09:45	45	Immunoh
		unknown
09:50 - 10:10	20	Coffee
10:10 - 10:40	30	Optimizat
		controls -
10:45 - 11:30	45	Immunoh
		unknown
11:35 - 12:05	30	Optimizat
		controls -
12:10 - 13:00	50	Lunch
13:00 - 13:45	45	Immunoh
		tumours -
13:50 - 14:20	30	Optimizat
		controls -
14.25 - 14:45	20	Coffee
14:45 - 15:30	45	Immunoh
		haematol
15:35 - 16:20	45	Optimizat
		controls -
16:25 - 16:40	15	Discussio



11:35 - 12:05

30

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



controls -

Discussio



HO Committee MADO.

New terms changed or entities added since 2004 WHO Classification.

15:35 - 16:20

LCNEC, large cell neuroendocrine carcinoma, WHO, World Health Organization;

16:25 - 16:40

Program	PRE	LIMINARY	ction.)	
LWAdge Cayr Eripte	nitrea 20th	TABLE 1. 2015 WHO Classification of Lu	ung Tumors ^{a,b,c}	TABLE 1. (Continued)	Nordi	C	
09:30 - 10:00		Histologic Type and Subtypes	ICDO Code	Histologic Type and Subtypes	ıс іРго gram		
	Arrival, coffee	Epithelial tumors	8140/3	Papillomas	Wednesday	, Septe	mber 20
10:00 - 10:15 15	Welcome and	introduction	8250/3 ^d	Squamous Alpapilloma Exophytic	⁸⁰⁵⁹ /.30 – 10:00	,	Arrival, o
10:15 - 11:00 45	Immunohistoc	hemicaldeprimciples:	8551/3 ^d 8260/3	Inverted	\$053/0 \$1,0000 - 10:15	15	Welcome
		est Migropapilaro den Chrinoma pre-ar		Glandular papiloma Se I Mixed squamous and glandular papilloma	8 1 60/015 - 11:00	45	Immuno
11:05 - 11:50 45		henricalucprinciples:	8253/3 ^d	Adenomas Sclerosing pneumocytoma ^e	$^{8832/0}_{875}$ 05 - 11:50	45	The tech Immuno
11.05 11.50 45		Mixed invasive mucinous and invasive mucinou	alvtica/seta	Alveolar acen N	8251/0 - 11.30 8260/0	45	The tech
12.00 12.15		Colloid adapagarainama	8480/3	Mucinous cystadenoma	8 1 7 2 /000 - 12:45	45	Immuno
12:00 - 12:45	Immunonistoc	hemical captainciples:	8333/3 . 8144/3 _	Mucous gland adenoma Mesenchymal tumob	8480/0		The tech
	The technical t	:estmapproachbearcinanalyti	cal phase I	Pulmonary hamartoma	12:45 - 13:30	45	Lunch
12:45 - 13:30 45	Lunch	Nonmucinous Mucinous	8256/3 ^d 8257/3 ^d	Chondroma PEComatous tumors ^e	9123/630 - 14:15	45	Immuno The tech
13:30 - 14:15 45	Immunohistoc	hemical principles:		Lymphangioleiomyomatosis	⁹ 174/ 1 20 - 15:05	45	Immuno
13.30 14.157		Trypical agenomatous hyperplasia	8250/0 ^d	PEComa, buyes Clear cell tumor			The tech
	,	est approach - analyti	- 6230/2	recoma, mangnant	$^{8005/0}_{8}$ 45/305 - 15.25	20	Coffee
14:20 - 15:05 45		hemical principles:	8253/2 ^d 8070/3	Congenital peribronchial myofibroblastic tumor Diffuse pulmon Nymphangiomatosis	8 1 2 5 /125 – 16:10	45	Immuno
	The technical t	estrapproachu-apost-a	nalyticarpha	ISE In lammatory myofibroblastic tumor	$^{8825/1}_{016}$ 15 - 17:00	45	The tech Immuno
15:05 - 15.25	Coffee	Nonkeratinizing squamous cell carcinoma ^e Basaloid squamous cell carcinoma ^e	8072/3 8083/3	Epithelioid hemangioendothelioma Pleuropulmonary blastoma	9 133/3 13 - 17.00 8973/3	73	tumours
15:25 - 16 10 45	T	Preinvasive lesion		Synovial sarcoma	9147/300 - 19.00		Social ar
10.25 - 10,10	Thiritationistoc	Neuroendocrine tumors	8070/2	Pulmonary arrary intimal sarcoma Pulmonary mysela sarcoma with EWSR1-CREB1 translocati See Mysepithelial tumors ^e	one 84hursday, Se	eptemb	er 21 st
				ISE Mydepithelial tumors	.08:15 - 09:00	45	Optimiza
16:1/5 - 17:00 45	I mmunohistoc	hemical classification	of breast	Myoepithelioma Myoepitheli Al kardi noma	8982/0 1 3 0 3 . 0 0 8982/3	45	controls
	tumours	Combined large cell neuroendocrine carcinom	a 8013/3	Myoepithelia va dinoma Lymphohistiocytic tumors	09:00 - 09:45	45	Immuno
17.00 - 19.00	Social arrange	Carcinoid tumors mentical continuo al) — Ked	alecnil 8/499 kit	Extranodal marginal zone lymphomas of mucosa-associa			unknowr
		menta (optional) - Keo	8249/3	Diffuse large cell lymphoma Lymphomatoid granulomatosis	99:50 - 10:10	20 30	Coffee
/ Thursday, Septemb	er 21 st	Preinvasive lesion Diffuse idiopathic pulmonary neuroendocrine	$8040/0^{d}$	Intravascular large B cell lymphoma ^c	9 10 /!10 - 10:40 9712/3	30	Optimiza controls
- · · -		cell hyperplasia	. 9012/2	Pulmonary Langerhans cell histiocytosis	$^{9751/1}_{0}$ 45 - 11:30	45	Immuno
08:15 - 09:00 45		f antibodies, selection	ı, protocols	Authors of ectoper disease Germ cell tumors	9/30/1		unknowr
	controls - brea	ast ^a tumours	8022/3	Germ cell tumors Teratoma, mature	11:35 - 12:05	30	Optimiza
09:00 - 09:45 45	Immunohistoc	hemical classification	of the8032/3	Teratoma, Manufer	9080/0 9080/1 8130/3 10 - 13:00	50	controls <i>Lunch</i>
		ary tumour - part I	8031/3 8980/3	Intrapulmonary thymoma Melanoma	8178/310 - 13:45	45	Immuno
00.50 10.10 30	·	Pulmonary blastoma	8980/3 8972/3	Meningioma, NOS	9530/0	-13	tumours
09:50 - 10:10 20	Coffee	Other and Unclassified carcinomas	9092/2	Metastatic tumors	13:50 - 14:20	30	Optimiza
10:10 - 10:40 30	Optimization o	f antibodies, selection	າ, protວັດວls	The morphology codes are from the ICDO. ² Behavior is coded or uncertain behavior, /2 for carcinoma intraepithelial neon stall and /3 for malignant tumors.	/0 for benign tumors, a in situ and grade III		controls
	controls - unk	nown brimary tumour	s part. Inc.	The classification is modified from the previous WHO class	14.25 - 14:45 ification ³ taking into 14:45 - 15:30	20 45	Coffee
10:45 - 11:30 45		hendroad stolassification	0 100/0	account changes in our understanding of these lesions. 'This table is reproduced from the 2015 WHO Classification by	Travis et al.1	45	Immuno haemato
10.15 11.50 49		arvetumiotema part II	8562/3 8940/0	These new codes were approved by the International Agency WHO Committee (1400). New terms changed or entities added since 2004 WHO Classif	on Cancer Research/	45	Optimiza
	ulikilowii DMM	arv: turruutum Daft II	0740/0	new terms changed or entities added since 2004 WHO Classif	iication.	_	

Optimization of antibodies, selection, protocols and continued antibodies and continued and continue

unknown primary turnour part II



Program

Immunohistochemcal classification of

Lung cancer,

Histologic Type and Subtypes

diagnosis and prediction.

TABLE 1. 2015 WHO Classification of Lung Tumors a,b,c



Immunoh

tumours Optimizat

controls -

Immunoh

haematol

Optimizat

controls -

Discussio

Coffee

20

15



Wadge Cayr Et pt on the 20th

09:30 - 10:00 Arrival, coffee

10:00 - 10:15 **15** Welcome and introduction

10:15 - 11:00 45 Immunohistochemical principles: The technical test approach - pre-analytical pha Immunohistochemical vaprincipules: 11:05 - 11:50 45

The technical test approach — pre-analytical bha 12:00 - 12:45 45 Immunohistochemical principles:

The technical test approach analytical phase I 12:45 - 13:30 45 Lunch

Immunohistochemiaalaprinaiples: 13:30 - 14:15 45 The technical test apprioach - analytical phase

14: 200 lignant spithelial t45 ors Immunohistochemical principles:

The technical test approach are post-analytical oh (carcinomas) 15:05 - 15.25 Coffee 20

15:25 - 16:10 45 Immunohistochemical principles: The technical test approach - post-analytical ph

Immunohistochemioa rolassification of breast 16:15 - 17:00 45 tumours

17.00 - 19.00Social arrandement (optional) - Keglespil k

Thursday, September 21st

08:15 - 09:00	45		tibodies, selection,	proteco
		controls - breast t	omatoid carcinomas Unopho UriSna	8022/3
09:00 - 09:45	45	Immunohistocher	incal action of	f the _{8031/3}
		unknown primary	turnour – part I	8980/3 8972/3
09:50 - 10:10	20	Coffee Other	er and Unclassified carcinomas	8082/3
10:10 - 10:40	30	Optimization of an	ymphoepithelioma-like carcinoma tipodies , selection .	

:©©ols controls - unknown primary tumours part by Immunohistochemical velassification of the s62/3

Basaloid squamous cell carcinomae

Combined large cell neuroendocrine carcinoma

Diffuse idiopathic pulmonary neuroendocrine

10:45 - 11:30 45 unknown primary tumour – part II 11:35 - 12:05 30 Optimization of antibodies, selection, protocols and

Melanoma

Meningioma, NOS

	Papillomas
8140/3	Squamous cell papilloma
8250/3 ^d	Exophyti SN
8551/3 ^d	Inverted
8260/3	Glandular pa <u>p</u> il <u>lom</u> a
8265/3	_Mixed squamous and glandular papilloma
al₃phase	Adenomas
8253/3 ^d	Sclerosing pneumocytoma ^e
	Alveolar adomorpa
8754/3h ac	Thapillary adenoma
រ្ត្រី _ន phase	Mucinous cystadenoma
8333/3	Mucous gland adenoma
8144/3	Mesenchymal tulk S
ase I	Pulmonary hamartoma
8256/3 ^d	Chondroma
8257/3 ^d	PEComatous tumors ^e
	Lymphangioleiomyomatosis
$8250/0^d$	PEComa, benigns
II	Clear cell tum
ase II	PEComa, malignant ^e
8253/2 ^d	Congenital peribronchial myofibroblastic tumor
8070/3	Diffuse pulmo ar lymphangiomatosis
ลืไ"ก้has	eInflammatory myofioroblastic tumor
80 / 2/15	Epithelioid hemangioendothelioma
8083/3	Pleuropulmonary blastoma
	Synovial sarcoma
8070/2	Pulmonary artery intimal sarcoma
	Pulmonary myxSq Arcoma with EWSR1-CREB1 translocation ^c
anpnas	eM oepithelial tumors ^e
8045/3	Myoepithelioma
ast	Myoepithelial carcinoma
8013/3	Lymphohistiocy (fix Minlors
02.40/2	Extranodal marginal zone lymphomas of mucosa-associated _ Lymphoid tissue (MALT lymphoma)
%(S kitt	Gasse large cell lymphoma
8249/5	Lymphomatoid granulomatosis
8040/0 ^d	Intravascular large B cell lymphoma ^c
0U4U/U	Pulmonary Langerhans cell histiocytosis
8012/3	Erdheim-Chester disease
	hing of ectopic grigin
	Til Til CINI°

	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
TABLE 1. (Continued)	
Histologic Type and Subtypes	^{ICD} Produram

· · · · · · · · · · · · · · · · · · ·	- Pro gram		
Papillomas	_		
Squamous cell papilloma	Wednesday, S	Septer	nber 20'
Exophyti S N	8052/0 8 Q9 630 - 10:00		Arrival, c
Inverted		4-	•
Glandular papilloma _Mixed squadou nd glandular papilloma	82100:00 - 10:15	15	Welcome
Adenomas	8560.15 - 11:00	45	Immunol
Sclerosing pneumocytoma ^e	8832/0		The tech
Alveolar ademornal	82 5 16 05 - 11:50	45	Immunol
Tapillary adenoma	8260/0		The techi
Mucinous cystadenoma	847% 00 - 12.45	45	Immunol
Mucous gland adenoma	$\frac{84720}{84800}$ 00 – 12:45	73	
Mesenchymal tuling	10.45 10.00		The techi
Pulmonary hamartoma	89 12 045 - 13:30	45	Lunch
Chondroma	⁹ 29 .30 – 14:15	45	Immunol
PEComatous tumors ^e	0174/1		The tech
Lymphangioleiomyomatosis	$^{9174/1}_{8744}20 - 15:05$	45	Immunol
PEComa, benigns Clear cell tunb	8005/0		The techi
PEComa, malignant ^c	87 15 305 - 15.25	20	Coffee
Congenital peribronchial myofibroblastic tumor	*15:25 - 16:10		
Diffuse pulmo@arNlymphangiomatosis	15:25 - 16:10	45	Immunol
Inframmatory invofioroblastic tumor	8825/1		The tech
Epithelioid hemangioendothelioma	9 1563:15 - 17:00	45	Immunol
Pleuropulmonary blastoma	8973/3		tumours
Synovial sarcoma	$\frac{901973}{9137/3}$ 00 - 19.00		Social ar
Pulmonary artery intimal sarcoma			
Pulmonary myx rcoma with EWSR1-CREB1 translocation ^c	⁸ Tੀਜੰursday, Sept	tembe	er 21 st
Myoepithelioma	8 08 915 - 09:00	45	Optimiza
Myoepithelial carcinoma	8982/3		controls
Lymphohistiocyth Uniors		4-	
Extranodal marginal zone lymphomas of mucosa-associated	909;00 - 09:45	45	Immunol
Lymphoid tissue (MALT lymphoma)			unknown
Gississe large cell lymphoma	⁹ 69.50 - 10:10	20	Coffee
Lymphomatoid granulomatosis	$^{976}_{97}$ 0;10 - 10:40	30	Optimiza
Intravascular large B cell lymphoma ^e Pulmonary Langerhans cell histiocytosis	9751/1		controls -
Erdheim-Chester disease	9750:45 - 11:30	45	Immunol
Bin of ectopic origin	740.45 11.50	43	unknown
Germ cell tunes	11.25 12.05	20	
Teratoma, mature	11:35 - 12:05	30	Optimiza
Teratoma, inputative Intrapulmonary mymoma	9080/1		controls
Intrapulmonary in Inoma	85\2310 - 13:00	50	Lunch

82/193.00 - 13:45

<u>16:2</u>5 - 16:40

This table is reproduced from the 2015 WHO Classification by Travis et al. 4:45 - 15:30

VHO Committee MADO.

New terms changed or entities added since 2004 WHO Classification.

15:35 - 16:20

LCNEC, large cell neuroendocrine carcinoma, WHO, World Health Organization

CDO International Classification of Diseases for Oncology.



Lung cancer,

Histologic Type and Subtypes

diagnosis and prediction.

TABLE 1. 2015 WHO Classification of Lung Tumors^{a,b,c}





Wadge dayr Eiptenpea 20th

09:30 = 10:0010:00 - 10:15 15 10:15 - 11:00 45

45

45

20

45

45

45

45

20

30

45

30

11:05 - 11:50 45 12:00 - 12:45 45

Adenocarcinoma Squamous carcinoma

Program

Large cell netirosendocrafie carrentelles:

Small cell carcinoma

15:25 - 16:10

08:15 - 09:00

09:00 - 09:45

09:50 - 10:10

10:10 - 10:40

10:45 - 11:30

11:35 - 12:05

16:15 - 17:00 17.00 - 19.00

rrra-		
Arrival,	coffee	
		١.

Welcome and introduction Immunohistochemical principles: The technical test approach - pre-analytical phase Alenomas

Immunohistochemical vaprincipules: Immunohistochemical principles:
The technical test approach pre-analytical pre-analytical pre-analytical test approach pre-analytical pre-ana

Immunohistochemical principles: The technical test approach an alytical phase I Lunch

Immunohistochemical principles:

The technical test approach - analytical phase II

The technical test approach are post-analytical phase Coffee

Immunohistochemical principles:

Immunohistochemioa rolassification of breast

tumours

Thursday, September 21st

Social arrangement (arring far in order) - Keglespil (2) Kittle Sk large cell lymphoma

Basaloid squamous cell carcinomae

Diffuse idiopathic pulmonary neuroendocrine

Combined large cell neuroendocrine carcinoma

Optimization of antipodies, selection, protocols controls - breast tumours Immunohistochemical ciassification of the 031/3

unknown primary tumour - part I Coffee

controls – unknownerprimary tumours part 1/3 Immunohistochemical velassification of the s62/3

unknown primary tumour – part II Optimization of antibodies, selection, protocols and

TABLE 1. (Continued)	<u>N</u> oral Q C	
Histologic Type and Subtypes	Program	
Papillomas Squamous cell papilloma	∞ W ednesday, Sep	tember 20 ^t
Exophyti S N Inverted	$^{8052/0}_{809030}$ 30 - 10:00	Arrival, co

Inverted Glandular papilloma Mixed squaknous and glandular papilloma 82/00:00 - 10:15 8560:15 - 11:00 8832/0 82**1**10 05 - 11:50 Sclerosing pneumocytoma^e

Mucous gland adenoma esenchymal tu A Pulmonary ham

PEComatous tumors Lymphangioleiomyomatosis PEComa, benigns

PEComa, malignant^e ongenital peribronchial myofibroblastic tumor

 $8250/0^{d}$

8140/3

8250/3

8551/34

 $8040/0^{d}$

ulmonary mys rcoma with EWSR1-CREB1 translocation The technical testalapproach post-analytical phase Mapithelial tumors

Melanoma

Myoepithelial carcinoma
ymphohistiocynt tunors extranodal marginal zone lymphomas of mucosa-associated Lymphoid tissue (MALT lymphoma)

ntravascular large B cell lymphoma

Germ cell tuns Teratoma, mature Teratoma, impatur

Meningioma, NOS morphology codes are from the ICDO.³ Behavior is coded /0 for benign tumors, begined borderling or uncertain behavior 0.2.2.6.

Optimization of antibodies, selection, protocols and properties of antibodies and protocols Salivary gland-type tumors.

Salivary gland-type tumors.

The classification is modified from the previous WHO classification and protocols. The classification is modified from the previous WHO classification and protocols. ount changes in our understanding of these lesions.

'This table is reproduced from the 2015 WHO Classification by Travis et al. 4:45 - 15:30

HO Committee MACDO.

New terms changed or entities added since 2004 WHO Classification.³ 15:35 - 16:20 LCNEC, large cell neuroendocrine carcinoma, WHO, World Health Organization DO International Classification of Diseases for Oncology. 16:25 - 16:40

84720.00 - 12:45

89b2645 - 13:30

92439:30 - 14:15

9174/1 814:20 - 15:05

87157:05 - 15.25

8827¹:25 - 16:10

91615 - 17:00

 $^{9040/3}_{017/3}$ 00 - 19.00

808q15 - 09:00

ൂറ്റു:00 – 09:45

969.50 - 10:10

 ${}^{97601}_{97103}$; 10 - 10:40

9750:45 - 11:30

11:35 - 12:05

8582310 - 13:00

82793.00 - 13:45

Welcome Immunoh The techr Immunoh The techr

45

20

50

20

15

Immunoh The techr Lunch Immunoh The techr

Immunoh The techr Coffee Immunoh

The techr Immunoh tumours Social arr

8 Thursday, September 21st Optimizat controls -Immunoh

> unknown Coffee Optimizat controls -

> Immunoh unknown Optimizat controls -

Lunch Immunoh tumours Optimizat controls -

Coffee Immunoh haematol Optimizat

controls -Discussio



Lung cancer,

diagnosis and prediction.



Program

Wadge dayr Eiptenfra 20th

		rrra- ⁻						
09:30 -10:00		Arrival, coffee						
10:00 - 10:15	15	Welcome and introduc	ction	SN				
10:15 - 11:00	45	Immunohistochemical		ON				
			roach — pre-analytical-phase I	<u></u>				
11:05 - 11:50	45	Immunohistochemical		P _{ON}			2014	2
		The technical test app	roach ellere-analytical phase II	_		$\overline{}$	14,7	
12:00 - 12:45	45	Immunohistochemical	principles: Storcellet neurgendokrint karcir	_ dMB			0,8	
12.45 12.20	4 -		Udra amå addat karainam					
12:45 - 13:30 13:30 - 14:15	45 45	Lunch	Ikke småcellet karcinom				12,0	
	45	The technical test ann	Principe fisher karcinom	_MB /			18,0	
Adenocarcinoma	45	Immunohistochemical	roach - analytical phase II Adenokarçinom principles:			$\overline{}$	39,9	
Squamous carcinom	na	The technical test app	Stockelleb karcian oneal phase I	SN			0,3	
Large 5 ell neuroend 15:25 - 16:10 Small cell carcinoma	l 20 rir	ne carcinoma	Adenoskvamøst karcinom		0,3		0,6	
15:25 - 16:10 Cm3 call carein amo	45	Immunohistochemical	principles Neuroendokrin tumor gach - post analytical phase II	SN	0,7	-	0,9	
		• •			1,6	-	1,1	
16:15 - 17:00	45		Anden malign primær lungecan	AVL		_		
17.00 10.00		tumours		cer (NOS)	3,9	_	4,0	
17.00 - 19.00			ptional) – Keglespil (<mark>Skittles</mark>) Blandingstunior		1,7	L	2,5	
Thursday, Septe	embe	r 21 st	Ingen patologi		5,4		5,2	
08:15 - 09:00	45		AintaFalartion protocols and	SN	4.706		4.733	4
00-00 00-45	45	controls – breast tumo		NAV /		_		
09:00 - 09:45	45	Immunohistochemical		MV				
09:50 - 10:10	20	unknown primary tum Coffee	Patologity	ne	2016	2015	2014	,
10:10 - 10:40	30	Ontimization of antiho	Sienacselleckionci protocols and and					-
10.10 - 10.40	30	controls - unknown n	rimary fumours part I Storce liet neuroendokrint karcir	SN			15,4	
10:45 - 11:30	45	Immunohistochemical	Storcenet neuroendokrint karcin classification of the		0,9	0,8	0,8	
201.10 22.00	••	unknown primary tum	classification of the like spacellet karcinom	MV	9,2	10,4	12,3	
11:35 - 12:05	30		offlesnoselection, karotocous and	SN	13,3	13,3	12,1	
								_



Lung cancer,

diagnosis and prediction.



Program

Wadge dayr & ptepper 20th

Lung Care		111a-3	
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunol istopped in lorgitimes: sampling The technical test approach – pre-analytical phase IS	ON
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
12:45 - 13:30	45	Linch Diagnosis	
13:30 - 14:15	45	Immunchistochemical principles: The technical principles: The technical principles:	assis (TN
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I representation (8th Edition)	SN
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach post analytical phase II Immunohistochemical Classification of breast	Stage IB
16:15 - 17:00	45		T2a _{Centr} N0
17.00 - 19.00	la -	Social arrangement (optional) – Keglespil (skittles)	T2a N0 (>3 ≤4 cm)
Thursday, Septe	embe	mucosal tumor	•

marsaay, sep	CIIIDC	21	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the Tiabe NI unknown primary tumour parts I	T3 _{Satell} N0
09:50 - 10:10	20	Coffee T3 _{Inv} N0 { T2a N1	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part	SM
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN


Lung cancer,

diagnosis and prediction.













Lung cancer,

diagnosis and prediction.




















Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th


09:30 - 10:00 10:00 - 10:15 10:15 - 11:00	15 45	Arrival, coffee Welcome and introduction Immunohistochemical principles:	Nچ ON
11:05 - 11:50	45	Inmunohistochemical principles: The technical test approach – pre-analytical phase I The technical test approach – pre-analytical phase II	ON
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	MB P
12:45 - 13:30	45	Lunch	D
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	MB
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immu Bødnist iochemical principles: The technical test approach - post-analytical phase II	SN
16:15 -/17:00	§ 45	Immunohistochemical classification of breast tumours	AVL
17.00 - 19.00		Social arrangement (optional) Keglespil (Skittles)	1
Thursday, Sep	tembe	r 21st	

Thursday, September 21st

			F-100
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	SN
The second second	4	controls – breast tumours	
09:00 - 09:45	*45	Immunohistochemical classification of the	MV
A LONG		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	CN
经 公司		controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the	MV
		Natiunknown primary tumour - part II	I*I V
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CNI

Bronkialwash*
Brushbiopsy*
EBUS*

Biopsy §





Lung cancer,

diagnosis and prediction.

TREELMINART

ord**iQC**

Program Wednesday, September 20th

	_			
09:30 - 10:00		Arrival, coffee		
10:00 - 10:15	15	Welcome and intro	duction	SN
10:15 - 11:00	45	Immunohistochem	ical principles:	ON
		The technical test a	approach – pre-analytical pbase I	OIV
11:05 - 11:50	45	Immunohistochem	ical principles:	ON
		The technical test a	approach – pre-analytical phase II 🤊	ON
12:00 - 12:45	45	Immunohistochem	ical principles:	МВ
		The technical test a	approach - analytical phase I 🎇	IMD.
12:45 - 13:30	45	Lunch		
0 - 14:15	45	Immunohist	cal principles:	MD
		The technica	pproach - analytical phase II	MB .
0 - 15:05	45	Immunohisto	cal principles:	CNI
LEAST STATE		The technica	pproach - post-analytical phase I	SN
5 - 15.25	20	Coffee		
5 - 16:10	45	Immunohisto	cal principles:	SN
	5065	The technica	pproach - post-analytical phase II	SIN
5 - 17:00	45	Immunohisto	cal classification of breast	AVL
A Marie The Control		tumours		AVL
0 - 19.00		Social arrang	(optional) Keglespil (Skittles)	
rsday, Sept	embe	r 21st		
- Application	1000	The second secon	., ,.	
5 - 09:00	45		ibodies, selection, protocols and	SN
00.45	4-	controls – br	imours	
0 - 09:45	45		cal classification of the	MV /
0 10-10	20		umour – part I	
0 - 10:10	20	Coffee		
0 - 10:40	30			SN
10.45 11.20	100 (S)	controls – ur	primary tumours part I	H
10:4 5 - 11:30	45		ical classification of the	MV
11.25 12.05	20	unknown primary t	•	
11:35 - 12:05	30	Optimization of ant	tibodies, selection, protocols and	SN



Immunohistochemcal classification of Periferal tumor Central tumor Lung cancer, diagnosis and prediction. **Tumor Diagnosis** Fine- or Bronchial brushing, Course needle Bronchial lavage, biopsi Tissue Biopsi Tumor type Diagnosis of metastases **EBUS** N **EUS** Fine- or courseneedle biopsi M from metastasis suspekte areas (found by CT eller PET scan)

Not operabel

Operabel





Lung cancer,

diagnosis and prediction.



Program


Wednesday Sentember 20th

wednesday, se	pten	
09:30 - 10:00		Arrival, coffee
10:00 – 10: Mediast	i ne sc	COPYIcome and introduction
10:15 - 11:00	45	Immunohistochemical principles:
		The technical test approach – pre-analytical phase I
11:05 - 11:50	45	Immunohistochemical principles:
	1	The technical test approach – pre-analytical phase II
12:00 lpcist2:45	45	Immunohistochemical principles:
		The technical dest approach - analytical phase I
Ridh21145 - 13:30	45	Lunch
13:30 - 14:15	45	Immunohis tochemical principles:
		The technical test approach—analytical phase II
14:20 - 15:05	45	Immunohistochemical principles:
		The technical Learner proach post-analytical phase I
15:05 - 15.25	20	Coffee
15:2 <mark>5 - 16:10</mark>	45	Immunohistochemical principles:
		The technical test approach - post-analytical phase II
16:1 <mark>5 - 17:00</mark>	45	Immunohistochemical classification of breast
		tumours National Cancer Institute
17.00 - 19.00		Social arrangement (optional) – Keglespil (Skittles)

Thursday, September 21st

	ALCOHOL: VALVA	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and
The state of the s		controls – breast tumours
09:00 - 09:45	45	Immunohistochemical classification of the
		unknown primary tumour – part I
09:50 - 10:10	20	Coffee
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and
		controls – unknown primary tumours part I
10:45 - 11:30	45	Immunohistochemical classification of the
DOMESTIC CONTRACTOR OF THE SECRETARY	A STATE OF THE PARTY OF THE PAR	unknown primary tumour – part II
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and

EBUS, EUS






AVL

SN


MV


SNI



Lung cancer,

diagnosis and prediction.





Not operabel

Operabel





Lung cancer,

diagnosis and prediction.



Program

10:45 - 11:30

11:35 - 12:05

45

30

Wed	lnesday, Se	epten	nber 20 th		
09:30	- 10:00		Arrival, coffee		
10:00	- 10:15	15	Welcome and introduction	Fine ^S Needle	biopsy
10:15	- 11:00	45	Immunohistochemical principles:	ON	J. 5 P 5 /
	Coarse nee	dle b	i σρεχ echnical test approach – pre-analytical phase I	I	
11:05	- 11:50	45	Immunohistochemical principles:	ON	
	11111	Bio	The technical test approach – pre-analytical phase I	100000	
A 12:00	12:45		mmunohistochemical principles:	MB	
12.4	6	int	seπthe technical test approach - analytical phase I		
	13:30		er lattinch		
1360	14:15	4 5 "	mgmmunohistochemical principles:	MB	
1120			The technical test approach - analytical phase II Immunohistochemical principles:	CODY	(1)
14:20 Body	3.05		The technical test approach - post-analytical phase	SN	
wall	= 15.25	76	Coffee	1	
DISABLE TO COME	- 16:40 _{nor}	45	Immunohistochemical principles:		
	±0. +umor		The technical test approach - post-analytical phase	SN	
16:15	- 17:00	45	Immunohistochemical classification of breast	The State of	
	-10		tumours	AŸL	© Mayo Foundation for Med
17.00	- 19.00		Social arrangement (optional) - Keglespil (5k)	s)	
	cday Sonto	mbo	1 8)		
	sday, Septe				
08:15	- 09:00	45	Optimization of antibodies, selection, protocols ar	nd SN	
	00.45		controls – breast tumours		
09:00	- 09:45	45	Immunohistochemical classification of the	MV	
00.50	10.10	20	unknown primary tumour – part I		
	- 10:10	20	Coffee	م م	
10:10	- 10:40	30	Optimization of antibodies, selection, protocols are	^{na} SN	
			controls – unknown primary tumours part I		

Immunohistochemical classification of the

Optimization of antibodies, selection, protocols and

unknown primary tumour – part II



MV

SN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th anatomical specimen

10:00 - 10:15 Welcome and introduction **15**

Immunohistochemical principles: 10:15 - 11:00 45 ON The tochnical test approach - pre-analytical phase I

oclemical principles: ON stapproach – pre-analytical phase II

Immunohistochemical principles: MB

The technical test approach - analytical phase I Lunch

Fixation Immunohistochemical principles:

Dehydratione technical test approach - analytical phase II

Parafinempedelingal test approach - post-analytical phase I

Micro My Coffee

Immunohistochemical principles:

The technical test approach - post-analytical phase II

45 Immunohistochemical classification of breast tumours

17.00 - 19.00Social arrangement (optional) - Keglespil (Skittles)



MB


SN

SN


AVL

08:15 -	09:00	45	Optimization of antibodies election, probable and controls breast upon	5N
09:00 -	09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 -	10:10	20	Optimization of antibodies, selection, potocols and	
10:10 -	10:40	30	Optimization of antibodies, selection, potocols and controls – unknown primary tumours part I	SN
10:45 -	11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 -	12:05	30	Optimization of antibodies, selection, protocols and	

Patient selection in lung cancer: Evolution over time



Patient selection in lung cancer: Evolution over time





Lung cancer,


diagnosis and prediction.



Program

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
Morpholo 11:05 - 11:50	45 ØV	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	2 _{4/5}	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
12.45 12.20	4-	, , , , , , , , , , , , , , , , , , , ,	



12:45 -	13:30	45 <i>L</i>
13:30	THE RESERVE AND ADDRESS OF THE PARTY OF THE	45
14:20 -	15:05	45
mon to		
15:05 - 15:25 -	15.25 16:10	20 V (
16:15 -	17:00	45

08:15 - 09:00


mmunohistochemical principles: The technical test approach - analytical phase II mmunohistochemical principles: The technical test approach - post-analytical phase I Coffee

mmunohistochemical principles: he technical test approach - post-analytical phase II mmunohistochemical classification of breast

MB

SN

AVL.



17.00 - 19.00 Social arrangement (optional) – Keglespib (Social screen)

Small cell carcinoma


Thursday, September 21 Squamous carcinoma

45

neuroendocrine carc. Optimization of antibodies, selection, protocols and

09 Mon 45 malt Ciental - breast tumours (NSWLC)

	unknown primary tumour – part I	
09:50 - 10:10 20	Coffee	
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 – 11:30 45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and	SN





Lung cancer,

diagnosis and prediction.



Kromogen (farvestof)

Visualiseringssystem Sekundært antistof Primært antistof Cellens cytoplasma Cellekerne

Program

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
Immumohi	Stoc	Welcome and introduction neuropische wical principles: The technical test approach – pre-analytical phase I Immunohistochemical principles:	ON
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
12:45 - 12:3 6 13:30 - 14:45	45 45	Immunohistochemical principles:	56


Caso Immunohistechemical principles: The technical test approach - analytical phase

Large cell

Immunohistochemical principles: The technical test approach - post-analytical phase Coffee Immunohistochemical principles: The technical test approach - post-analytical phase. Immunohistochemical classification of bre tumours ** Social arrangement (optional) - Keglespil

cd56

DAB



Small cell carcinoma

08:15 - 09:00	na 45	Squamous carcinoma Optimization of antibodies, selection pewrocenschotr	inę, carc	Small cell carcinon
09:00 - 09:45	45	controls – breast tumours Immunohistochemical classification of the	MV _	
09:50 - 10:10	20	unknown primary tumour – part I Coffee Neur	oendo	ocrine carc.
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN	
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN	



Lung cancer,

diagnosis and prediction.



Kromogen (farvestof)

Visualiseringssystem Sekundært antistof Primært antistof Cellens cytoplasma Cellekerne

Program

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
Immumohis	sto (neuropiscelle vical principles: The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
12:45 - 13:3 f 13:30 - 1 4:4 5	45	Lunch p63	54
13:30 - 14:45	45	Immunohistochemical principles:	

13:30 - 14:45

Immunohistochemical principles: The technical test approach - analytical phase

Immunohistochemical principles: The technical test approach - post-analytical phase Coffee

Immunohistochemical principles:


The technical test approach - post-analytical phase. Immunohistochemical classification of bre

tumours **

Social arrangement (optional) - Keglespil

cd56

DAB



Small cell carcinoma

Thursday, September 21st Adenocarcinoma 08:15 - 09:00 45 Optimization of antibodies, selection newrocandocrine carc

controls - breast tumours

Non 5 09:45 II	C ₂₀ ⁴⁵ II	Immunohistochemical classification of the International Confee (NSCL	$\overset{MV}{C}$
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CN

Lung cancer,


diagnosis and prediction.

Algorithm modified from


Diagnosis of Lung Cancer in Small Biopsies and Cytology


Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Yuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Fleeder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thunnissen, MD; Ming Tsao, MD



Lung cancer, diagnosis and prediction.







Diagnosis of Lung Cancer in Small Biopsies and Cytology


Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Iravis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Vuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Flieder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thunnissen, MD; Ming Isao, MD



Lung cancer, diagnosis and prediction.







Diagnosis of Lung Cancer in Small Biopsies and Cytology


Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Iravis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Tuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Hieder, MD; Wilbur Iranklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thumissen, MD; Ming Isao, MD



Lung cancer, diagnosis and prediction.







Diagnosis of Lung Cancer in Small Biopsies and Cytology


Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Tuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Hieder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thumissen, MD; Ming Tsao, MD




Lung cancer, diagnosis and prediction.






CD56




Diagnosis of Lung Cancer in Small Biopsies and Cytology

Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Tuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Hieder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thumissen, MD; Ming Tsao, MD




Lung cancer, diagnosis and prediction.






Chromogranin A



Diagnosis of Lung Cancer in Small Biopsies and Cytology


Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification


William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Vuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Flieder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thumitiseen, MD; Ming Tsao, MD




Lung cancer,

diagnosis and prediction.






Synaptophysin




Diagnosis of Lung Cancer in Small Biopsies and Cytology

Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Iravis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Vuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Flieder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thunnissen, MD; Ming Isao, MD




Lung cancer, diagnosis and prediction.






Cytokeratin




Diagnosis of Lung Cancer in Small Biopsies and Cytology


Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Tuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Hieder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thumissen, MD; Ming Tsao, MD




Lung cancer, diagnosis and prediction.






ttf



Diagnosis of Lung Cancer in Small Biopsies and Cytology


Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification


William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Tuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Hieder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thumissen, MD; Ming Tsao, MD




Lung cancer,


diagnosis and prediction.







Lung cancer,









Lung cancer,








P63+ (+Cytokeratin 5/6)



Lung cancer,







Lung cancer,


diagnosis and prediction.







Adenocarcinoma





CK5/6

P63


Lung cancer,

diagnosis and prediction.









Napsin

CK5/6

P63

Squamous carcinoma



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09 <u>:</u> 30 - 10:00	Arrival, coffee	
144roblems.15	Welcome and introduction	SN
10:15 - 11:00 45	Immunohistochemical principles:	ΟN
11:05 - 11:50 45	And technical test approach - pre-analytical phase II	P63-
12:00 - 12:45 45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
12:45 - 13:30 45	Lunch	
13:30 - 14:15 45	Immunohistochemical principles: The technical test approach 7 analytical phase II	MB
14:20 - 15:05 45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN
15:05 – 15.25 20	Coffee	
15:25 – 16:10 45	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN
16:15 - 17:00 45	Immunohistoche <mark>mical classification of breast tumours</mark>	AVL
17.00 - 19.00	Social arrangement (optional) - Keglespil (Skittles)	
	7	

Thursday, September 21st

08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CN

p40 is the Best Marker for Diagnosing Pulmonary Squamous Cell Carcinoma: Comparison With p63, Cytokeratin 5/6, Desmocollin-3, and Sox2

Takahiro Tatsumori, MD,*† Koji Tsuta, MD, PhD,* Kyohei Masai, MD,* Tomoaki Kinno, MD,* Tomoko Taniyama, MD,* Akihiko Yoshida, MD, PhD,* Kenji Suzuki, MD, PhD,† and Hitoshi Tsuda, MD, PhD*



Lung cancer,





Program

Wednesday, September 20th

09:30 - 10:00 10 Proble 10:15 - 11:00	MS!5 45	Arrival, coffee Welcome and introduction Immunohistochemical principles:	SN	
11:05 - 11:50	45	The technical test approach – pre-analytical phose II The technical test approach – pre-analytical phase II	P63+	•
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ	
12:45 - 13:30	45	Lunch No. Cases (%) Immunoreactivity	,	
13:30 - 14:15	M at F er	Immunohistochemical principles: Positive	e MB	Mean Staining Score (0-300)
14:20 - 15:05	p40 p63 45	The technical test approach - analytical phase II 153 (96. Immunohistochemical principles: 150 (97. The technical test approach - post-analytical phase I		169 237
15 ^N 05 ^{SQQ} 5.25	p40 20	Coffee 418 405 (96.9) 13 (3.1)		1.3
15:25 - 16:10	p63 45	Immunohistochemical principles: The technical test approach - post-analytical phase II) SN	16.9
16:15 - 17:00	45	Immunohistochemical classification of breast tumourskin breast prostate	AVL	
17.00 - 19.00	D(2 A)	Social arrangementr(toptional) - Keglespil (Skittles)		
Theresa does Co	LO2 H	Dast A		

Thursday, September 21st

1Apo3	ТАРОЗ
08:15 - 09:00	Optimization of antibodies, selection of is the Best Manker for Diagnosing Pulmonary
<u> </u>	controls - breast tumours Squamous Cell Carcinoma: Comparison With p63, Immunohistochemical classification of the location 5/6. Desmocollin 3, and Sov 3
09:00 09:45 mitment	Immunohistochemical classification of the Cantilloria. Companion with pos,
ectoderm	Linknown primary tumour - part I Cytokeratin 5/6, Desmocollin-3, and Sox2
ectodeiiii	unknown primary tumour – part I Cytokeratin 5/6, Desmocollin-3, and Sox2
09:50 - 10:10	20 liferativ€ Office Takahiro Tatsumori, MD,*† Koji Tsuta, MD, PhD,* Kyohei Masai, MD,* Tomoaki Kinno, MD,*
10:10 - 10:40	30° Optimization of antibodies, selection, protocols and Akihiko Yoshida, MD, PhD, Kenji Suzuki, MD, PhD,†
	controls – unknown primary tumours part I
10.45 11.20	·
10:45 - 11:30	45 Immunohistochemical classification of the

MV

unknown primary tumour – part II

11:35 – 12:05

30

Optimization of antibodies, selection, protocols and SNI



diagnosis and prediction.



Program

Wednesday, September 20th

Wednesday, Septer	
09:30 - 10: Table 2. Se	ensitivity repecificity, PPV and NPV of markers used in this
10:00 - 10:5 udv [% 5p	OWNTOP (and interduction)] SN
10.15 - 11 <u>.00 </u>	Trimunonistochemical principles.
11:05 - 11:50 Marker S	Subtype in Senestiality (%) - Sie en appelle progre PPV (%) NPV (%)
ΔNp63 (p40)	\$00 (16/16) 100 (32/32) \$10 (32/32) \$10 (32/32) \$10 (32/32) \$10 (32/32)
12:00 - 12:45 45 ′ 45 ′ p63	Immunohistochemical principles: Shectechnical Qost 1964 Sch - analysidal ghazz); 80MB6/20) 100 (28/28)
12:45 - 13:30 13:30 - 14:15 45	81 (13/16) 100 (32/32) 100 (13/13) 91 (32/35)
34βE12	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$
14:20 - 15:05 45 TTF1	Immunohistochemical principles: The technical less of pastantal principles: 1
15:05 - 15.25 15:25 - 16:10 20 45	Coffee 64 (16/25) 100 (23/23) 100 (16/16) 72 (23/32) Immunohistochemical principles:
CK7	The technical the principles. The technical the principles is a second
16:15 - 17:00 45 CK8/18	Immunohistochemical classification of breast $t\Delta\Omega$ ours $100 (25/25)$ $35 (8/23)$ $63(25/40)$ $100 (8/8)$
17.00 - 19.00 Sensitivity = T	- Social arrangement (optional) - Keglespil (Skittles) P/TP+FN: Specificity = TN/TN+FP: Positive predictive value (PPV) = TP/
Thursday, Septembe	ive predictive value (NPV) = TN/TN+FN. FN indicates false negatives; FP,
08:15 - 09:00 false positives	Optimization of antibodies, selection, protocols and so the same of antibodies, selection, protocols and so
09:00 - 09:45 45	Immunohistochemical classification of the UClin Exp Pathol 201 M/V :4247-4253 unknown primary tumour – part I www.ijcep.com/ISSN:1936-2625/UCEP0000624
09:50 - 10:10 20	Coffee
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part Np63, CK5/6, TTF-1 and napsin A, a reliable panel to
10:45 - 11:30 45	Immunohistochemical classification of the MV unknown primary tumour – part II
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and SN



diagnosis and prediction.



Program

11:35 - 12:05

30

Wednesday, September 20th

09:30 - 10: Table 2. Sensitivity repecificity, PPV and NPV of markers used in this 10:00 - 10:5 udy [% powertond introduction)] SN ON PPV (%) 11:05 - 11:50 **NPV** (%) $\Delta Np63(p40)$ 100 (32/32) Immunohistochemical principles: 12:00 - 12:45 80MB6/20) 100 (28/28) FRE technical Cost 166166ch - analysis (28/32) 12:45 - 13:30 13:30 - 14:15 Sunch 81 (13/16) 100 (32/32) Immunohistochemical principles: 45 100 (13/13) 91 (32/35) 45 47 (15/32) \$10@technica型控练性更ppf6ach - ana4yti(组5/1632) II 94 (15/16) 34BE12 14:20 - 15:05 Immunohistochemical principles:
The technical less propriate principles:
The technical less propriate principles:

1 87 (20/23) 45 TTF1 80 (20/25) 15:05 - 15.25 15:25 - 16:10 A *Coffee* 20 ACCCC 64 (16/25) 100 (23/23) Immunohistochemical principles: 100 (16/16) 72 (23/32) 45 The technical dest 29 p 203 ch - post 3 5 48 to 28 p hase II 63 (25/40) 100 (8/8) CK7 Immunohistochemical classification of breast 16:15 - 17:00 45 634(25/40) 100 (8/8) CK8/18 100 (25/25) tAmours 35 (8/23) 17.00 – 19.00 — Social arrangement (optional) – Keglespil (Skittles) Sensitivity = TP/TP+FN; Specificity = TN/TN+FP; Positive predictive value (PPV) = TP/ Thursday, September 21st Negative predictive value (NPV) = TN/TN+FN. FN indicates false negatives; FP, 08:15 - 09:00 false positives; Optimization of antibodies selection protocols and controls - breast tumours 09:00 - 09:45 45 Immunohistochemical classification of the J Clin Exp Pathol 201 MV 3:4247-4253 www.ijcep.com /ISSN:1936-2625/IJCEP0000624 unknown primary tumour - part I 09:50 - 10:10 Coffee 20 Optimization of antibodies, selection, projects and 10:10 - 10:40 30 controls - unknown primary tumours part Np63, CK5/6/NTTF-1 and napsin A, a reliable panel to Immunohistochemical classification of the ubtype non-small cell lung cancer in biopsy specimens 10:45 - 11:30 45 unknown primary tumour - part II

Optimization of antibodies, selection, protocols and CN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 - 10:00 10 Problems:	Arrival, coffee Welcome and introduction	SN
10:15 - 11:00 4	Immunohistochemical principles:	ON
11:05 - 11:50 4	The technical test approach – pre-analytical phase I Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON 3
12:00 - 12:45 4	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
12:45 - 13:30 4	• • • • • • • • • • • • • • • • • • • •	
13:30 - 14:15 4	Immunohistochemical principles: The technical test approach - analytical phase II	МВ
14:20 - 15:05 4	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN
15:05 – 15.25 2	Coffee	
15:25 - 16:10 4	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN

Differential diagnosis between primary and metastatic Social arrangement (optional) – Keglespil (Skittles)

Thursday, September 21st

30

11:35 - 12:05

carcinoma

08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the	MV
09:50 - 1 O the	r2q(2	unknown primary tumour – part I 10色10) Carcinomas are po Optimization of antibodies, selection, protocols and	ositive for ttfl
10:10 - 10:40	30'	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV

Optimization of antibodies, selection, protocols and



Lung cancer,

diagnosis and prediction.



Program

WednesdaymSeptembero20tbchemistry results.

09:30 - 10: <u>00</u>	Arrival, coffee		
10:00 - 10:15 15	Welcome and introduction Total cases SPT24	SN 8G7G3/1	P
10:15 - 11: 00 	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON	
11:05 – 11:50 Adenocar 4:5 om	a Immunohistochemical principles 185 134 (72.4%)	$ON^{121\ (65.4\%)}$	0.08
12:00 - 12:45 Large Cell	The technical test approach – pre-analytical phase II Immunohistochemical principles: 47	17(36.2%) MB	0.201
Carcinoid	The technical test approach - analytical phase [60.8%]	4(17.4%)	0.003
12:45 – 13:30	Lunch Immunohistochemical principles: 14(16.8%)	1(1.0%)	0.003
Unclassified	The technical test approach - analytical phase (45.5%)	MB _{7(31.8%)}	0.26
14:20 - 15:05 45	Immunohistochemical principles $_{98}$ $_{5,(5.1\%)}$ The technical test approach - post-analytical phase I	SN 5 (5.1%)	NS
15:05 – 15.2 ©olon 20	Coffee 120 3 (2.5%)	3 (2.5%)	NS
15:25 - 16:10 45	Immunohistochemical principles: $_{160}$ $_{2(1.2\%)}$ The technical test approach - post-analytical phase II	SN 2(1.2%)	NS
16:15 - 17:0 Stomach 45	Immunohistochemical classification of breast(0.9%)	AVL ^{1(0.9%)}	NS
Salivary Gland 17.00 - 19.00	tumours 56 1(1.8%) Social arrangement (optional) – Keglespil (Skittles)	1(1.8%)	NS
Thursday, Septembe	rcinoma of head and neck 38 0(0%)	0(0%)	NS
08:15 - 09:00 Pancreatic adend	Carcinomas $0(0\%)$ Optimization of antibodies, selection, protocols and	0(0%) SN 0(00()	NS
Breast	controls – breast tumours 34 0(0%)	0(0%)	NS
09:00 – 09: 45 45 NS: not significant	Immunohistochemical classification of the unknown primary tumour – part I	NIH Publi Author Manus	c Access cript to Mol Marchol. Author manuscript; available in PMC 2011 March 1.
09:50 - 10:10 20	Coffee	Published in final edited Appl Immunohistocher	d form as: m Mol Morphol. 2010 March; 18(2): 142-149. doi:10.1097/PAI.0b013e3181bdf4e7.
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	•	f thyroid transcription factor-1 expression by two
10:45 – 11:30 45	Immunohistochemical classification of the unknown primary tumour – part II	MV tumors	ntibodies in pulmonary and non-pulmonary primary
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and	Noble, Murray B. Re	snick, Ronald A. DeLellis, and Li J. Wang logy and Laboratory Medicine, Rhode Island Hospital and Brown Medical



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th On: 30 = 10:00 Arrival coffee Diagnosis of metastasis

09:30 - 10:00		Arrival, coffee
10:00 - 10:15	15	Welcome and introduction Immunohistochemical principles: to the lung
10:15 - 11:00	45	Immunohistochemical principles:
		The technical test approach – pre-analytical phase I
11:05 - 11:50	45	Immunohistochemic科評价模图 ON COON
	200	pro unary creat prideo 11
12:00 - 12:45	45	Immun <mark>ohistochemica Principles:</mark>
		The technical test appropriate analytical phase I in the technical test appropriate and the test appropriate analytical phase I in the technical test appropriate analytical phase I in the test appropriate analytical phase I in the test appropriate and the test appropriate analytical phase I in the test appropriate and the test appropriate and the test appropriate analytical phase I in the test appropriate and the test
12:45 - 13:30	45	Lunch
13:30 - 14:15	45	Immunohistochemica Principles:
		The technical test appreadn - analytical phas
14: 2 0 - 15:05	45	Immunohistochemical principles:
		The technical test apple to post-analytical process in the second post-analytical post-analytical process in the second post-analytical post-ana
15:05 - 15:25	20	Coffee ER ER
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post analytical series II
16: 4 5 - 17:00	1	
16:15 - 17:00	45	4 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2
17.00 40.00		Social arrangement (phonal) – Keglespil (Skittles)
17.00 - 19.00		
Thursday, Septe	mbe	r 21 st CK5/6
A PROTOTO OF THE PARTY OF THE P	000	

d SN
5.1
MV
id SN
SIN
MV
ITIV
d CN
1



Lung cancer,

diagnosis and prediction.



10:45 - 11:30

11:35 - 12:05

45

30

Program		PRELIMINARY	
Wednesday, Se	epter	Diagnosis of m	netastasis
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction to the L	IPNO
10:15 - 11:00	45	Tillingonistochemical principles.	ON
The second second second		The technical test approach – pre-analytical phase I	OIV .
11:05 - 11:50	45	Immunohistochemica Frinca E3	on Mamma
	100	The technical test approach – pre-analytical phase II	i laililla
12:00 - 12:45	45	Immunohistochemical principles:	MB
12.45 12.20		The technical test apprent - analytical phase I	
12:45 - 13:30	45	Immunohistochemical prosines:	
13:30 - 14:15	45		MB
14:20 - 15:05	45	The technical test apprace of analytical phase II Immunohistochemical principles:	
14,20 = 13,03		The technical test approach - post-analytical phase I	SN
15:05 - 15.25	20	Coffee FR	MATERIAL CONTRACTOR
15:25 - 16:10	45	Immunohistochemical principles:	
		The technical test approach postanalytical phase II	SN
16: 9 5 - 17:00	45	Immunohistochemic Assification of breast	A) (I
	1700	tumours	AVL
17.00 - 19.00		Social arrangement (V) (Social arrangement (V) (Social arrangement (V) (Social arrangement (S)	
Thursday, Septe	embe	er 21 st CK5/6	-
08:15 - 09:00	45	Optimization of antiboths, selection, protocols and	100
00.13	0	controls - breast tumo prs	SN
09:00 - 09:45	45	Immunohistochemical classification of the	MV
		unknown primary tur	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
		controls – unknown 🏳 🕰 tumours part I	NIC
10-45 11-20	4 =	T	

MV

SN

Immunohistochemical classification of the unknown primary tumour – part II

Optimization of antiboths Agestion, protocols and



diagnosis and prediction.



Program

Diagnosis of metastasis Wednesday, September 20th

09:30 - 10:00	Arrival, coffee
10:00 - 10:15 15	Welcome and introduction to the luftg
10:15 - 11:00 45	Immunohistochemical principles:
	The technical test approach – pre-analytical phase I
11:05 - 11 :50 45	Immunohistochemic和原物區多
•	
12:00 - 12:45 45	Immunohistochemica Principles:
	The technical test appropriate analytical phase
12:45 - 13:30 45	Lunch Nanein
13:30 - 14:15 / 45	Immunohistochemica Albeines:
	The technical test approximation phase
14:20 - 15:05	Immunohistochemical principles:
1505 3536	The technical test apploach - post-analytical p
15:05 - 15.25 20	Coffee ER
15:25 - 16:10 45	Immunohistochemical principles: The technical test approach - post analytical p
16: 4 5 - 17:00 45	
16: 1 5 - 17:00 45	Immunohistochemic
17.00 - 19.00	Social arrangement (bittonal) – Keglespil (Skittles)
	CK5/6

Thursday, Septer	nber 21st	UN3/6	-
08:15 - 09:00		ion of antib oos , selection, protoc	cols and SN
09:00 - 09:45	controis - 45 Immunoh	breast tumous 0	MV
09:50 - 10:10	unknown	primary tur RCO G part I	
10:10 - 10:40	20 <i>Coffee</i> 30 Optimizat	Ca125 tion of antibodies, selection, protoc	cols and
	controls -	- unknown 🏳 🕰 tumours part I	SN SN
10:45 - 11:30	45 Immunoh	nistochemical classification of the primary tumour – part II	MV
11:35 - 12:05		tion of antibod A A Section, protoc	cols and



diagnosis and prediction.



Program

10:45 - 11:30

11:35 - 12:05

Wednesday, September 20 th Diagnosis of metastasis 09:30 - 10:00 10:00 - 10:15 15 Welcome and introduction to the lung on the technical test approach - pre-analytical phase I 11:05 - 11:50 45 Immunohistochemical principles: The technical test approach - pre-analytical phase I 12:00 - 12:45 45 Immunohistochemical principles: The technical test approach - analytical phase I 12:45 - 13:30 15 Lunch 13:30 - 14:15 45 Immunohistochemical principles: The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: The technical test approach - post-analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: The technical test approach - post-analytical phase II 14:20 - 15:05 The technical test approach - post-analytical phase II 15 NB 16 NB 17 NB 17 NB 17 NB 18 NB 18 NB 18 NB 19 NB 19 NB 19 NB 19 NB 10 NB 10 NB 10 NB 10 NB 10 NB 11 NB 11 NB 11 NB 12 NB 13 NB 14 NB 15 NB 16 NB 17 NB 18 NB 1
10:00 - 10:15 10:15 - 11:00 45 Immunohistochemical principles: The technical test approach - pre-analytical phase I 11:05 - 11:50 45 Immunohistochemical principles: The technical test approach - pre-analytical phase I 12:00 - 12:45 45 Immunohistochemical principles: The technical test approach - analytical phase I 12:45 - 13:30 12:45 - 13:30 13:30 - 14:15 45 Immunohistochemical principles: The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: SN
The technical test approach – pre-analytical phase I 11:05 – 11:50 45 Immunohistochemical principles 12:00 – 12:45 45 Immunohistochemical principles The technical test approach – pre-analytical phase I 12:45 – 13:30 13:30 – 14:15 45 Immunohistochemical principles: The technical test approach – analytical phase I 14:20 – 15:05 45 Immunohistochemical principles: The technical test approach – analytical phase II 14:20 – 15:05 45 Immunohistochemical principles: The technical test approach – analytical phase II 14:20 – 15:05 45 Immunohistochemical principles: SN
The technical test approach – pre-analytical phase I 11:05 – 11:50 45 Immunohistochemical principles 12:00 – 12:45 45 Immunohistochemical principles The technical test approach – pre-analytical phase I 12:45 – 13:30 13:30 – 14:15 45 Immunohistochemical principles: The technical test approach – analytical phase I 14:20 – 15:05 45 Immunohistochemical principles: The technical test approach – analytical phase II 14:20 – 15:05 45 Immunohistochemical principles: The technical test approach – analytical phase II 14:20 – 15:05 45 Immunohistochemical principles: SN
Immunohistochemical Frinches 12:00 - 12:45 45 Immunohistochemical Frinches The technical test approach - pre-analytical phase II 12:45 - 13:30 45 Immunohistochemical Principles The technical test approach - analytical phase I 12:45 - 13:30 45 Immunohistochemical Principles: The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: SN SN SN SN SN SN SN SN SN S
The technical test approach – pre-analytical phase II 12:00 – 12:45 45 Immunohistochemical phinciples The technical test approach – analytical phase II 12:45 – 13:30 13:30 – 14:15 45 Immunohistochemical principles: The technical test approach – analytical phase II 14:20 – 15:05 45 Immunohistochemical principles: The technical test approach – analytical phase II 14:20 – 15:05 The technical test approach – analytical phase II 14:20 – 15:05
12:00 - 12:45 45 Immunohistochemical principles: The technical test approach - pre-analytical phase II 12:45 - 13:30 13:30 - 14:15 45 Immunohistochemical principles: The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: The technical test approach - analytical phase II Immunohistochemical principles: SN
12:45 - 13:30 45 Lunch 13:30 - 14:15 45 Immunohistochemical principles: The technical test approach—analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: SN
12:45 - 13:30 45 Lunch 13:30 - 14:15 45 Immunohistochemical principles: The technical test approach—analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: SN
13:30 – 14:15 45 Immunohistochemical principles: The technical test aportage phase II 14:20 – 15:05 45 Immunohistochemical principles:
The technical test ap properties of the properties of the technical test ap properties of the technical test approperties of the technical test appropriate of the t
14:20 - 15:05 45 Immunohistochemical principles:
A A L L L
the technical test anakhach - nost-analytical phase
CONTROL OF THE PROPERTY OF THE
15:05 - 15:25 20 Coffee ER
15:25 – 16:10 45 Immunohistochemical principles: The technical test approach - post analytical phase II
是基础。1000年,1000年,1000年,1000年的1000年的1000年的1000年的1000年的1000年的100年的1000年的1000年的1000年的1000年的1000年的1000年的1000年的1000年的
tumours 17.00 – 19.00 Social arrangement (phonal) – Keglespil (<u>Skittles</u>
Thursday, September 21 st CK5/6
09:15 00:00 /F Optimization of antibody solection protocols and
controls breast turgours of
controls - breast tumous 09:00 - 09:45 45 Immunohistochemical classification of the MV
unknown primary tur Acu G part I
09:50 - 10:10 20 Coffee Ca125.

SN

MV

SN

10:10 – 10:40 **20** Coffee Cal 25
10:10 – 10:40 **30** Optimization of antibodies, selection, protocols and controls – unknown Fig. 8 tumours part I

45

30

Immunohistochemical classification of the unknown primary tumour – part II

Optimization of antibook\$A@ection, protocols and



diagnosis and prediction.



Program

10:45 - 11:30

11:35 - 12:05

45

30

Wednesday, September 20th Og: 30 - 10:00 Arrival coffee Diagnosis of metastasis

09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction to the lumpupohistochemical principles:	IPNO
10:15 - 11:00	45	Immunohistochemical principles:	
		The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemic	ON .
	10.70	The technical test approach – pre-analytical phase I	näl cell carcinoma
12:00 - 12:45	45	immunonistochemicar principies:	MB
		The technical test appropriate analytical phase	
12:45 - 13:30	∂ 45	Lunch	
13:30 - 14:15	45	Immunohistochemica Analyses:	MB
		The technical test appropriate analytical phase	
14:20 - 15:05	45	Immunohistochemical principles:	SN
		The technical test application - post-analytical p	
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post analytical p	SN
a_			B. T.
16: 1 5 - 17:00	45	Immunohistochemic Assification of breast	AVL
	1000/200	tumours	
17.00 - 19.00	4.5	Social arrangement (Vinal) Keglespil (Skittles	
Thursday, Sept	embe	r 21 st CK5/6	
08:15 - 09:00	45	Optimization of antibotos, selection, protoco	
		controls - breast tumous	SIN
09:00 - 09:45	45	Immunohistochemical classification of the	MV
		unknown primary turn G part	
09:50 - 10:10	20	Coffoo	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	CNI
		controls – unknown RAX tumours part I	SN

Immunohistochemical classification of the unknown primary tumour – part II

Optimization of antibo AFA ection, protocols and

MV

SN



Lung cancer,

diagnosis and prediction.



Ultrasound probe

Program

Wednesday, Se	eptember 20 th	Diagnosis of	metastasis
09:30 - 10:00	Arrival coffee		

09:30 - 10:00		Arrival, coffee	100000010
10:00 - 10:15	15	Welcome and introduction to the I	ING
10:15 - 11:00	45	Immunohistochemical principles:	
		The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemic Frinche S	Prostate_
		The technical test approach – pre-analytical phase II	
12:00 - 12:45	45	Immunohistochemica Phihciples:	MB
12 45 12 20		The technical test appropriate - analytical phase I	
12:45 - 13:30	45	Lunch Immunohistochemical ansines:	
13:30 - 14:15	45		МВ
14:20 - 15:05	45	The technical test apprace of analytical phase II Badde Immunohistochemical principles:	
14.20 = 15.05	10	The technical test applicate - post-analytical phase I	SN
15:05 - 15.25	20		
15:25 - 16:10	45	Immunohistochemical principles:	
BELLET BET ACRESSED FOR ACTIVE ACRESSED FOR THE	97457 AND	The technical test approach postanalytical phase II	SN
16: 1 5 - 17:00	45	Immunohistochemic A Saksification of breast	A) /II Rectum
	1700	tumours	AVL
17.00 - 19.00		Social arrangement (Villonal) – Keglespil (<u>Skittles</u>)	
Thursday, Septe	mbe	cr 21 st CK5/6	AND MINES
08:15 - 09:00	45	Optimization of antibolog, selection, protocols and	SN
		controls – breast tumous of the Immunohistochemical classification of the	SIN
09:00 - 09:45	45		MV
A CONTRACTOR OF THE PARTY OF TH		unknown primary tur RCC part I	
09:50 - 10:10	20	Ca125 Optimization of antibodies, selection, protocols and	
10:10 - 10:40	30		SN
10-45 11-20	4=	controls – unknown FiAX8 tumours part I	
10:45 - 11:30	45	Immunohistochemical classification of the	MV
11:35 - 12:05	30	unknown primary tumour - part II Optimization of antibooks Agection, protocols and	
11.33 - 12.03	30	Optimization of antibophets Agection, protocols and	SN



diagnosis and prediction.

CK5/6



Program

Diagnosis of metastasis Wednesday, September 20th

09:30 - 10:00		Arrival, coffee
10:00 - 10:15	15	Welcome and introduction Immunohistochemical principles: The technical test approach – pre-analytical phase I
10:15 - 11:00	45	Immunohistochemical principles:
	Section 1	The test approach pre analytical phase i
11:05 - 11:50	45	Immunohistochemica Frincia Sering Francisco Fr
	20 B	The technical test approach - pre-analytical phase HIIOUIIICUI al Calice
12:00 - 12:45	45	Immunohistochemica Porinciples:
A STATE OF THE STA		The technical test approach - analytical phase
12:45 - 13:30	45	Lunch
13:30 - 14:15	45	Immunohistochemica Pariples:

The technical test appricable - analytical phase 14:20 - 15:05 Immunohistochemical principles: 45 The technical test apple - post-analytical p 15:05 - 15.25 20 Coffee

Immunohistochemical principles:
The technical test approach postanalytical p 15:25 - 16:10 45

16:**4**5 - 17:00 45 Immunohistochemic sification of breas tumours

Social arrangement (Villonal) - Keglespil (Skine 17.00 - 19.00

Thursday, September 21st


08:15 - 09:00 Optimization of antibotos, selection, protoc 45 controls – breast tumoயுs o Immunohistochemical classification of the

09:00 - 09:45 45 unknown primary tur

09:50 - 10:10 Coffee 20 Ca125
Optimization of antibodies, selection, protocols and 10:10 - 10:40 30 SN controls – unknown PAXI8 tumours part I

10:45 - 11:30 45 Immunohistochemical chasification of the MV unknown primary tumour – part II

Optimization of antibooks Agection, protocols and 11:35 - 12:05 30



SN

SN



Lung cancer,

diagnosis and prediction.

Optimization of antibo AFA ection, protocols and



Program

11:35 - 12:05

30

Diagnosis of metastasis Wednesday, September 20th

_		2 145110010 01 111004004010
09:30 - 10:00		A suring a large field
10:00 - 10:15	15	Welcome and introduction Immunohistochemical principles: The technical test approach are applytical phase I
10:15 - 11:00	45	Immunohistochemical principles:
1.10		The technical test approach – pre-analytical phase i
11:05 - 11:50	45	Immunohistochemic本原作版图
	See See Mark	
12:00 - 12:45	45	Immunohistochemica Phincipies.
		The technical test appropriate - analytical phase
12:45 - 13:30	6 45 √	Lunch
13:30 - 14:15	45	Immunohistochemical Appliples:
		The technical test aportage - analytical phase III
14:20 - 15:05	45	Immunohistochemical principles:
		The technical test applican - post-analytical phase
15:05 - 15.25	20	Coffee ER
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post analytical prase II
16: 4 5 - 17:00	45	Immunohistochemic Assification of breast AVL
	Comment of the	: tumours
17.00 - 19.00		Social arrangement (Villonal) – Keglespil (S <mark>klates</mark>)
Thursday, Sep	tembe	r 21 st CK5/6
08:15 - 09:00	45	Optimization of antiboos, selection, protocols
00.13 - 09.00	0	
09:00 - 09:45	45	controls – breast tumoயு of the Immunohistochemical classification of the
09.00 - 09. 1 3		unknown primary turniuG part I
09:50 - 10:10	20	Coffee
10:10 - 10:40	20	Optimization of antibodies, selection, protocols and
TOTTOTTOTTO	STATE OF THE	controls – unknown FAX8 tumours part I
10:45 - 11:30	45	Immunohistochemical classification of the
10.42 - 11.20	73	unknown primary tumour – part II
		anknown printary turnour part if



diagnosis and prediction.



Program

10:45 - 11:30

11:35 - 12:05

45

30

Wednesday, Se	eptember 20 th	Diagnosis of metastasis
09.30 - 10.00	Arrival coffee	6

Immunohistochemical classification of the unknown primary tumour – part II

Optimization of antiboths Agection, protocols and

	Diagnosis of meascasis
09:30 - 10:00	Arrival, coffee
10:00 - 10:15 15	Welcome and introduction Immunohistochemical principles: to the luftg
10:15 - 11:00 45	Immunohistochemical principles:
	The technical test approach – pre-analytical phase I
11:05 - 11:50 45	Immunohistochemic科斯伊多
	Immunohistochemic和原物區多 The technical test approach – pre-analytical phase II Thyroid cancer
12:00 - 12:45 45	Immunohistochemical principles: MB
	The technical test appropriate test appropriat
12:45 - 13:30 45	Lunch
13:30 - 14:15 / 45	Immunohistochemical apsiples:
	The technical test appressing analytical pr
14:20 - 15:05 45	Immunohistochemical principles:
The second second	The technical test approach - post-analytic
15:05 - 15.25 20	Coffee FR 1
15:25 – 16:10 45	Immunohistochemical principles: The technical test approach - postanalytic
	The technical test approach postanalytic
16: 4 5 - 17:00 45	immunohistochemic அது sification of br
	tumours
17.00 - 19.00	Social arrangement (Vittonar) Keglespi
Thursday, Septemb	er 21 st CK5/6
08:15 - 09:00 45	Optimization of antibolog, selection, pro
<u> </u>	controls – breast tumoயுs 0 Immunohistochemical classification of th
09:00 - 09:45 45	
	unknown primary tur RCC part I
09:50 - 10:10 20	Ca125 Optimization of antibodies, selection, protocols and
10:10 - 10:40 30	
	controls – unknown 🗗 🕰 😸 tang part I

MV

SN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th Diagnosis of metastasis

09:30 - 10:00		Arrival, coffee
10:00 - 10:15	15	Welcome and introduction to the luftg
10:15 - 11:00	45	Immunohistochemical principles:
		The technical test approach – pre-analytical phase I
11:05 - 11:50	45	Immunohistochemical principles:
	Pa Pa	The technical test approach – pre-analytical phase II
12:00 - 12:45	45	Immunohistochemical principles:
10000		The technical test application in the
12:45 - 13:30	45	Lunch WT1
13:30 - 14:15	45	Immunohistochemical principles:
	most of	The technical test approach - analytical phase
14:20 - 15:05	45/	Immunohistochemica principles:
		The technical test approach - post-analytical pase
15:05 - 15.25	20	Coffee VIM
15:25 - 16:10	45	Immunohistochemicalogiples:
		The technical test approach - post-analytical phase
16:15 - 17:00	45	Immunohistochemical classification of breast
	tone file	tumours
17.00 - 19.00		Social arrangement (optional) – Keglespil (<mark>S<mark>kittes</mark>)</mark>
Thursday, Sept	embe	r 21st
oout oo oo	05 m 10 A	

MV
ols and SN
SIN
MV
۱۳۱V
ols and



Lung cancer,

diagnosis and prediction.




Program

Wednesday, September 20th

Wednesday, Se	PtCII	iibei 20	
09:30 <u>- 1</u> 0:00 _		Arrival, coffee	
10:00 1	1 5	twilding maintaining ry Taama	Mnfaranca
10:15 J 11:5 V	45	tipisciplinary Teamo	<u>Minerence</u>
		The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemical plintiples:	ON
		The technical test approach —pre-analytical phase II	014
12:00 - 12:45	45	Immunohistochemical principles:	МВ
12:45 12:20	4=	The technical test approach - analytical phase I	
12:45 - 13:30	45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles:	MB
14:20 - 15:05	45	The technical test approach - analytical phase II Immunohistochemical principles:	ALCOHOL: NAME OF TAXABLE PARTY.
14.20 - 15.05		The technical test approach - post-analytical phase I	SN
15:05 - 15.25	20	Coffee	100 (100 mm)
15:25 - 16:10	45	Innrounchistochemical principles:	- TANK A CONT.
		The technical test approach - post-analytical phase II	SN
16:15 - 17:00		Immunohistochemical classification of breast	AVL
		mours	AVL
17.00 - 19.00		cial arrangement (optional) - Keglespil (Skittles)	
Thursday, Sep		The state of the s	- m
08:15 - 09:00	+	Optimization of antibodies, selection, protocols and	
00:13 05:00		controls - breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the	MV
		unknown primary tumour – part I	AT THE REAL PROPERTY.
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	
		controls – unknown primary tumours part I	314
10:45 - 11:30	45	Immunohistochemical classification of the	MV
11.05.10.05		unknown primary tumour – part II	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN


Lung cancer,













Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th anatomical specimen

10:00 - 10:15 Welcome and introduction 15

10:15 - 11:00 45 Immunohistochemical principles:

The technical test approach – pre-analytical phase I 11:05 - 11:50

45 Immunohistochemical principles: Histology **45** The technical test approach - pre-analytical

Immunohistochemical principles:

The technical test approach - analytical phase I

Lunch

Fixation Immunohistochemical principles:

Dehydratione technical test approach - analytical phase II

Parafinembed And test approach - post-analytical phase I

Micro***O**my^{Coffee}

Immunohistochemical principles:

The technical test approach - post-analytical phase II


45 Immunohistochemical classification of breast

tumours

17.00 - 19.00Social arrangement (optional) - Keglespil (Skittles)

Thursday, September 21st

08:15 -	09:00	45	Optimization of antibodies election, protocols and controls breat upon	5N
09:00 -	09:45	45	Immunohistochemical classification of the unknown primary tumour – part I.	MV
09:50 -	10:10	20	Optimization of antibodies, selection, potocols and	
10:10 -	10:40	30	Optimization of antibodies, selection, potocols and controls – unknown primary tumours part I	SN
10:45 -	11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 -	12:05	30	Optimization of antibodies, selection, protocols and	CN



MB

SN

SN

AVL





Lung cancer,

diagnosis and prediction.



Program

Wednesday, Sentember 20th

	weunesuay, se	pten	ibel 20"		
	09:30 - 10:00		Arrival, coffee		
	10:00 - 10:15	15	Welcome and introduction	SN	
	10:15 - 11:00	45	Immunohistochemical principles:	ON	
			The technical test approach – pre-analytical phase I	ON	
	11:05 - 11:50	45	Immunohistochemical principles:	ON	
	10.00 10.45		The technical test approach – pre-analytical phase II		
	12:00 - 12:45	45	Immunohistochemical principles:	МВ	
	12.45 12.20	4 =	The technical test approach - analytical phase I		
	12:45 - 13:30	45	Lunch		
	13:30 - 14:15	45	Immunohistochemical principles:	МВ	
			The technical test approach - analytical phase II		
	14:20 - 15:05	45	Immunohistochemical principles:	SN	
			The technical test approach - post-analytical phase I	511	
	15:05 - 15.25	20	Coffee		
	15:25 - 1 6:10	45	Immunohistochemical principles:	SN	
			The technical test approach - post-analytical phase II	SIN	
	16:15 - 17:00	45	Immunohistochemical classification of breast	AVL	- 2
4		No.	tumours	AVL	
	17.00 - 19.00		Social arrangement (optional) - Keglespil (Skirles)	0 20	
	Thursday, Septe	mbe	r 21 st	W 10 - 10 - 10 - 10 - 10 - 10 - 10 -	
	08:15 - 09:00				
A	08.13 - 09.00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN	
	00.00 00.45	ΔE	Immunohistochomical classification of arge Cell	MV	
	09:00 - 09:45 Adenocarcinom	45 a	Immunohistochemical classification of the cell unknown primary carcinomart I neuroendocr		S
,			unknowith primary tuniour part I neuroendocr	ine carc.	_



Small cell carcinoma

09:50 - 10:10 20 Corree 10:10 - 10:40

10:45 - 11:30

11:35 - 12:05

45

Shirba Funknown primar/theous part CINO
Immunohistochemical classification of the
unknown primary to our – part II

30

Optimization of antibodies, selection, protocols and

MV



Lung cancer,

diagnosis and prediction.

Optimization of antibodies, selection, protocols and



Program

11:35 - 12:05

30

Wednesday, September 20 th				
,	15	Arrival, coffee Welcome and introduction C01-5229 KC01-5229	SN	
10:15 - 11:00	45	Immunohistochemical principles The technical test approach pre-analytical phase I	ON	
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach — pre-analytical phase II	ON	
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ	
12:45 - 13:30	45	Lunch		
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	МВ	
A	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN	
15:05 - 15.25	20	Coffee		
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN	
16:15 - 17:00	45	Immunohistochemical classification of breast tumours	AVL	
17.00 - 19.00		Social arrangement (optional) – Keglespil (<u>Skittles</u>)		
Thursday, Septer	mbe	r 21 st		
08:15 - 09:00	45	optimizations of the property of the controls breast tumours	SN	
09:00 - 09:45	45	Immunohistochemical classification of the	MV	
		unknown primary tumour – part I		
09:50 - 10:10	20	Coffee		
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN	
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV	

Morfologi

Cellblock

Immunocytologi←



Lung cancer,

diagnosis and prediction.



Program

Wednesday,	September 20 th
------------	----------------------------

Wednesday, Se	pten	nber 20 th	
09:00 TICOO OSY	15	Arrival, coffee 1. Centrifuger materialet 10 min. ved 3000 omdr./min. 2. Hæld supernantanten fra. SN	dnr
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach — pre-analytical phase I Immunohistochemical principles: Immunohistoch	Innelse
11:05 - 11:50	45	The technical test approach — pre-analytical phase II will be a second test approach.	e at
12:00 - 12:45	45	Immunohistochemical principles: en gazepose, træk den over reagensglasset. MB The technical test approach: - Indalytical phase I.	Koag
12:45 - 13:30	45	Lunch 9. Læg posen i en kapsel med mikroskopi-nummeret.	5
13:30 48 (D)	745 K	Lunch 9. Læg posen i en kapsel med mikroskopi-nummeret. Immunohistochemical principles et par dråber hæmatein på koaglet. MB	<u>o</u>
		The technical test approach 1-1 and lytical ephasened 4% neutralt buffet formaldehyd.	
14:20 -Immuncyto	•	The technical test approach - post-analytical phase I	_
15:05 - 15.25	20	Coffee	=
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post-analytical phase II	Par
16:15 - 17:00	45	Immunohistochemical classification of breast tumours	Paratir
17.00 - 19.00	400	rangement (optional) – Keglespil (<u>Skittles</u>)	
Thursday, Septe	mbe		
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and SN controls - breast tumours	
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	Indstøbning
09:50 - 10:10	20	Coffee	9
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and SN	2
10.45 - 11:30	45	controls — unknown primary tumours part I Immuno istochemical classification of the unknown primary tumour – part II	gn
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and SN	



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:00 - 10:00	Arrival, coffee	
	Welcome and introdu <mark>ction</mark>	SN
10:15 - 11:00 45	Immunohistochemica <mark>l principles:</mark>	ON
	The technical test ap <mark>proach – pre-analytical phase I</mark>	ON
11:05 - 11:50 45	Immunohistochemica <mark>l principles:</mark>	ON (A)
	The technical test approach – pre-analytical phase II	SIT IN
12:00 – 12:45 45	Immunohistochemica <mark>l principles:</mark>	MB NB
12.45 12.20 45	The technical test approach - analytical phase I	
12:45 - COLL 13:30 1 1 1 1 1 1 1 1 1	Kunch Immunohistochemical principles:	
13:30 - 461 (D (046		МВ
14:20 - Immuncytokog	The technical test approach - analytical phase II Immunohistochemical principles:	
14.20 TIMIMUNICY TO HEAD	The technical test approach - post-analytical phase I	SN
15:05 - 15.25 20	Coffee	
15:25 - 16:10 45	Immunohistochemical principles:	•
	The technical test approach - post-analytical phase II	SN
16:15 - 17:00 45	Immunohistochemical classification of breast	A7.0
	tumours	AVL
17.00 - 19.00	Social arrangement (optional) - Keglespil (Skittles)	
Thursday, Septemb	er 21 st	
08:15 - 09:00 45	Optimization of antibodies, selection, protocols and	SN
colliantra	omacontrols — breast tum <mark>ours TEM Immunohistochemical classificat</mark> ion of the	SIN
09:00 09:45 IL 45		MV
	unknown primary tu <mark>mour – par</mark> t I	
09:50 - 10:10 20	Coffee	
10:10 - 10:40 30	Optimization of antib <mark>odies, selection, protocols and controls – unknown primary tumours part I</mark>	SN
10:45 - 11:30 45	Immunohistochemical classification of the	MV
	unknown primary tumour – part II	יין ע
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and	SN



Lung cancer,

diagnosis and prediction.



Program

14:20 - 15:0

15:05 - 15.25

15:25 - 16:10

16:15 - 17:00

17.00 - 19.00

Wednesday Sentember 20th

Wednesday, September 20 "				
09:00 - 40:00	,	Arrival, coffee		
09: y 10:00 ogy	15	Welcome and introduction		
10:15 - 11:00	45	Immunohistochemical principles:		
		The technical test approach – pre-analytical phase		
11:05 - 11:50	45	Immunohistochemical principles:		
		The technical test approach – pre-analytical phase		
12:00 - 12:45	45	Immunohistochemical principles:		
		The technical test approach vanalytical phase I		
12:45 13:30 DAB 13:30 14:15	45	Lunch		
13:30 - 14:15	45	Immunohistochemical principles:		
		The technical test approach - analytical phase I		

Immunohistochemical principles:


The technical test approach - post-analytical phase I Coffee Sekundært antistof

Coffee

Immunohistochemical principles:
The technical test approach - post-analytical phase II


Immunohistochemical classification of breast tumours

Social arrangement (optional) - Keglespil (Skittle Cellekerne



20

08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I
09:50 - 10:10	20	Coffee
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and







MV

SN

SN




Patient selection in lung cancer: Evolution over time



Lung cancer,

diagnosis and prediction.





Molecular analysis EGFR and ALK




Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th






Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th





Lung cancer,

diagnosis and prediction.



Program

11:35 - 12:05

30

Wednesday, September 20th

Optimization Optimization of antibodies, selection, protocols and controls Optimization of antibodies Optimization of the unknown primary tumour Optimization of the unknown primary tumour Optimization of the unknown primary tumour Optimizat	weanesaay,	Septen	iber 20"	
10:15 - 11:00 45 Immunohistochemical principles: Unknown the dechnical test approach - pre-analytical phage is (35%) 11:05 - 11:50 45 Immunohistochemical principles: The technical test approach - pre-analytical phage II 12:00 - 12:45 45 Immunohistochemical principles: The technical test approach - analytical phase II 12:45 - 13:30 45 Lunch 13:30 - 14:15 45 Immunohistochemical principles: The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: The technical test approach - post-analytical phase II 15:05 - 15:25 20 Coffee 15:25 - 16:10 45 Immunohistochemical principles: The technical test approach - post-analytical phase II 16:15 - 17:00 KIF45TET Immunohistochemical classification of breast tumours Social arrangement (optional) - Keglespil (Skittles) Thursday, September 21st EGFR (15%) 08:15 - 09:00 45 Optimization of antibodies, selection, protocols and controls - brinciples and controls - unknown primary tumour - part I 09:50 - 10:10 20 Coffee 10:10 - 10:40 30 Optimization of antibodies, selection, protocols and controls - unknown primary tumour part I 10:45 - 11:30 45 Immunohistochemical classification of the unknown primary tumour part I SN MB Gene Mutation SN Gene Fusion AVE Gene Amplification Inknown SN SN SN SN SN MV MV		4=	Arrival, coffee	rinoma
Unknown The technical test approach - pre-analytical phase Is (35%) 11:05 - 11:50 45		_		og Norma
11:05 - 11:50 45 Immunohistochemical principles: The technical test approach - pre-analytical phase II 12:00 - 12:45 45 Immunohistochemical principles: The technical test approach - analytical phase II 12:45 - 13:30 45 Lunch 13:30 - 14:15 45 Immunohistochemical principles: The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: The technical test approach - analytical phase II 15:05 - 15:25 20 Coffee 45os Immunohistochemical principles: The technical test approach - post analytical phase II 16:15 - 17:00 KIFSTET Immunohistochemical principles: The technical test approach - post analytical phase II 16:15 - 17:00 KIFSTET Immunohistochemical classification of breast tumours Social arrangement (optional) - Keglespil (Skittles) Thursday, September 21st Coffee 45 Immunohistochemical classification of the unknown primary tumour - part I 09:50 - 10:10 20 Coffee 10:10 - 10:40 30 Optimization of antibodies, selection, protocols and controls - unknown primary tumours part I 10:45 - 11:30 45 Immunohistochemical classification of the MV	10:15 - 11:00			ON
The technical test approach - pre-analytical phase II 12:00 - 12:45 45		Unknow	nline technical test approach – pre-analytical phase is	35%)
The technical test approach - pre-analytical phase II 12:45 - 13:30 45	11:05 - 11:50	45		ON
The technical test approach - analytical phase I 12:45 - 13:30				
12:45 – 13:30 45	12:00 - 12:45	45		MB
13:30 – 14:15 45 Immunohistochemical principles: The technical test approach - analytical phase II 14:20 – 15:05 45 Immunohistochemical principles: The technical test approach - post-analytical phase II 15:05 – 15.25 20 Coffee 15:25 – 16:10 45os Immunohistochemical principles: The technical test approach - post-analytical phase II 16:15 – 17:00 KIF351ET Immunohistochemical classification of breast tumours 17:00 – 19:00 Thursday, September 21st Optimization of antibodies, selection, protocols and controls - breast tumours 09:00 – 09:45 45 Immunohistochemical classification of the unknown primary tumour - part I 09:50 – 10:10 20 Coffee 10:10 – 10:40 30 Optimization of antibodies, selection, protocols and controls - unknown primary tumours part I 10:45 – 11:30 45 Immunohistochemical classification of the MV				
The technical test approach - analytical phase II 14:20 - 15:05 45		_		
The technical test approach - analytical phase II 14:20 - 15:05 45	13:30 - 14:15	45		MB
The technical test approach - post analytical phase I 15:05 - 15:25 20				=1
15:05 - 15.25 15:25 - 16:10 4	14:20 - 15:05	45		SN Come Mutation
15:25 - 16:10 45os Immunchistochemical principles: The technical test approach - post-analytical phase II 16:15 - 17:00 KIF 45 ET Immunchistochemical classification of breast tumours 17.00 - 19.00 Social arrangement (optional) - Keglespil (Skittles) Thursday, September 21st Controls - breast tumours 09:00 - 09:45 45 Optimization of antibodies, selection, protocols and controls - breast tumours 17.00 - 10:10 Optimization of antibodies, selection, protocols and controls - unknown primary tumour - part I 10:45 - 11:30 45 Immunchistochemical classification of the unknown primary tumours part I 10:45 - 11:30 MV MV				Gene Mutation
The technical test approach - post-analytical phase II 16:15 - 17:00 KIF 45 ET Immunohistochemical classification of breast tumours 77:00 - 19:00 Social arrangement (optional) - Keglespil (Skittles) Thursday, September 21st 08:15 - 09:00 45 Optimization of antibodies, selection, protocols and controls - breast tumours 09:00 - 09:45 45 Immunohistochemical classification of the unknown primary tumour - part I 09:50 - 10:10 20 Coffee 10:10 - 10:40 30 Optimization of antibodies, selection, protocols and controls - unknown primary tumours part I 10:45 - 11:30 45 Immunohistochemical classification of the				
The technical test approach - post-analytical phase II 16:15 - 17:00 KIF 45 ET Immunohistochemical classification of breast tumours 77:00 - 19:00 Social arrangement (optional) - Keglespil (Skittles) Thursday, September 21st 08:15 - 09:00 45 Optimization of antibodies, selection, protocols and controls - breast tumours 09:00 - 09:45 45 Immunohistochemical classification of the unknown primary tumour - part I 09:50 - 10:10 20 Coffee 10:10 - 10:40 30 Optimization of antibodies, selection, protocols and controls - unknown primary tumours part I 10:45 - 11:30 45 Immunohistochemical classification of the	15:25 - 16:10	4Fos	Immun <mark>c</mark> histochemi <mark>cal princi</mark> ples:	SN Gono Eusion
tumours Social arrangement (optional) - Keglespil (Skittles) Thursday, September 21 st 08:15 - 09:00 45 Optimization of antibodies, selection, protocols and controls - breast tumours 09:00 - 09:45 45 Immunohistochemical classification of the unknown primary tumour - part I 09:50 - 10:10 20 Coffee 10:10 - 10:40 30 Optimization of antibodies, selection, protocols and controls - unknown primary tumours part I 10:45 - 11:30 45 Immunohistochemical classification of the			The technical test approach - post-analytical phase II	Gene Fusion
Thursday, September 21st O8:15 - 09:00 45 Optimization of antibodies, selection, protocols and controls - breast tumours O9:00 - 09:45 45 Immunohistochemical classification of the unknown primary tumour - part I O9:50 - 10:10 Optimization of antibodies, selection, protocols and controls - unknown primary tumours part I O9:45 - 11:30 45 Immunohistochemical classification of the MV	16:15 - 17:00	KIF5B RET		AVI- Gene Amplification
Thursday, September 21 st 08:15 - 09:00 45 Optimization of antibodies, selection, protocols and controls - breast tumours 09:00 - 09:45 45 Immunohistochemical classification of the unknown primary tumour - part I 09:50 - 10:10 20 Coffee 10:10 - 10:40 30 Optimization of antibodies, selection, protocols and controls - unknown primary tumours part I 10:45 - 11:30 45 Immunohistochemical classification of the				•
08:15 – 09:00 45 Optimization of antibodies, selection, protocols and controls - breast tumours 09:00 – 09:45 45 Immunohistochemicalielassification of the unknown primary tumour – part I 09:50 – 10:10 20 Coffee 10:10 – 10:40 30 Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I 10:45 – 11:30 45 Immunohistochemical classification of the				- F Unknown
09:00 – 09:45 45 Immunohistochemicaliclassification of the unknown primary tumour – part I 09:50 – 10:10 20 Coffee 10:10 – 10:40 30 Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I 10:45 – 11:30 45 Immunohistochemical classification of the	Thursday, Se	ptembe	r 21 ^{st)} EGFR (15%)	
09:00 – 09:45 45 Immunohistochemicaliclassification of the unknown primary tumour – part I 09:50 – 10:10 20 Coffee 10:10 – 10:40 30 Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I 10:45 – 11:30 45 Immunohistochemical classification of the	08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	CN
unknown primary tumour – part I 09:50 – 10:10 20				SIN
09:50 – 10:10 20 Coffee 10:10 – 10:40 30 Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I 10:45 – 11:30 45 Immunohistochemical classification of the	09:00 - 09:45	45	Immunohistochemical classification of the	MV
10:10 – 10:40 Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I 10:45 – 11:30 45 Optimization of antibodies, selection, protocols and solution of the			unknown primary tumour – part I	
controls – unknown primary tumours part I 10:45 – 11:30 45 Immunohistochemical classification of the	09:50 - 10:10	20	Coffee	
10:45 – 11:30 Controls – unknown primary tumours part I Immunohistochemical classification of the	10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	CN
MV			• • • • • • • • • • • • • • • • • • • •	SIN
unknown primary tumour – part II	10:45 - 11:30	45	Immunohistochemical classification of the	N4) /
· · · · ·			unknown primary tumour – part II	IYI V

Optimization of antibodies, selection, protocols and

SN



Lung cancer,

diagnosis and prediction.



Program

11:35 - 12:05

30

Wednesday, September 20th

	vvcanesaay	, Septem		
	09:30 - 10:00	4=	Arrival, coffee Welcome and the duction were' in Adenocard	rinoma
	10:00 - 10:15	15		Siloma
	10:15 - 11:00	45	Immunohistochemical principles:	ON
		Unknow	The technical test approach – pre-analytical phase is (3	35%)
	11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON
	12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	МВ
D	12:45 - 13:30	45	Lunch Implication of the company of	
Pr	ECHAPAICE	mæfk	The technical test approach - analytical phase II	МВ
	14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN Gene Mutation
	15:05 - 15.25	20	Coffee	
	15:25 - 16:10	4 Rost	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN - Gene Fusion
	16:15 - 17:00	KIF5B-RET	Immunohistochemical classification of breast tumours	AV - Gene Amplification
	17.00 - 19.00		Social arrangement (optional) - Keglespil (Skittles)	- Unknown
	Thursday, S	eptembei	ER2 (2%) — EGFR (15%)	
	08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls - breast tumours	SN
	09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV
	09:50 - 10:10	20	Coffee	d: -4:
	10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	egictive marker
	10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV


Optimization of antibodies, selection, protocols and





Program

PRFI TMTNARY Oncogene 'drivers' in Adenocarcinoma






Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th



SN




Lung cancer,

diagnosis and prediction.



Program





Lung cancer,

diagnosis and prediction.



Program

• •	•		
09:30 - 10:00		Arrival, coffee	
	15	Welcome and introduction	SN
	45	Immunohistochemical principles:	ON
Oncogene 'drivers' in Adenocarcinoma		The technical test approach – pre-analytical phase I	ON
Oncogene 'drivers' in Adenocarcinoma 11:50	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase II	
12:00 - 12:45	45	Immunohistochemical principles:	МВ
- Gene Mutation		The technical test approach - analytical phase I	2
ROS1 (1%) 2 45 13:39 Gene Fusion KIFSB-RET (1.5%) Gene Amplifica	45	Lunch	
HER2 (::3) 3 : 39 11 15 EGFR (15%)	45	Immunohistochemical principles:	MB O
BRAF (4%) MET (4%)		The technical test approach analytical phase II and	Exon 21 L861
14:20 - 15:05	45	Immunohistochemical principles: DGFL858	SN W
15.05 15.25	A CO	The technical test approach - post-analytical phase I	
15:05 - 15.25	20	Coffee A767SVDNPHV	
15:25 - 16:10	457	Immunohistochemical principles:	SN G
16:15 - 17:00	45	The technical test approach - post-analytical phase II Immunohistochemical classification of breast	Ch DATA
10.15 - 17.00	-6	Exon 19	AVE 3
17.00 - 19.00		Social arrangement (optional) – Keglespil (Skittles)	
Thursday, Septe	mbe	F 21st T790 Exon 19	Exon 18
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and 15:	G719SGAFG (GXGXXG)
		controls – breast tumours	SIN
09:00 - 09:45	45	Immunohistochemical classification of the	MV
		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
		controls – unknown primary tumours part I	
10:45 - 11:30	45	Immunohistochemical classification of the	MV
11 25 12 05	20	unknown primary tumour – part II	
11:35 – 12:05	30	Optimization of antibodies, selection, protocols and	SN



Lung cancer,

diagnosis and prediction.



Program

14:20 - 15:05

15:05 - 15.25

15:25 - 16:10

16:15 - 17:00

17.00 - 19.00

Wednesday, September 20th

~45


45

20

45

45

ROS1 (1% 12 : 45 - 13 : 30 Gene Fusion	45	Lunch EGFR mutation positive	
- Gene Mutatio	on	The technical test approach - analytical phase I	סויו
1 <mark>2:00 -</mark> 12:45	45	Immunohistochemical principles:	МВ
		The technical test approach – pre-analytical phase II	ON
Unknown (325%) 1:05 11:50 KRAS (35%)	45	Immunohistochemical principles:	ON
Oncogene 'drivers' in Adenocarcinoma		The technical test approach – pre-analytical phase I	ON
	45	Immunohistochemical principles:	ON
	15	Welcome and introduction	SN
09:30 - 10:00		Arrival, coffee	



Thursday, Septemb

08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	CN
09:00 - 09:45	45	controls – preast tumous 16 20 24 0 Immunohistochemical classification of the	MV
		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	




Lung cancer,

diagnosis and prediction.



Program





Lung cancer,

diagnosis and prediction.



Program

09:30 – 10:00 Arrival, coffee Lung Cancer	icer
10.00 ±0.05	
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
The technical test approach - pre-analytical phase I	
Oncogene 'drivers' in Adenocarcinoma 11:05 11:50 45 Improve FCFR mulation specific antibodies for lung adenocarcinoma: Highly specific but not sensitive detection of an F746 A750 delawn in	sMark
12:00 - 12:45 45 The technical test approach - pre-analytical phase II exon 19 and an L858R mutation in exon 21 by immunohistochemistry Immunohistochemical principles: MB	
12:00 - 12:45 45 Immunohistochemical principles: Then be seen by James Barkles Kandings Ping Ji Sunga Hyojin Kimas MB	
The Nest of the State of the St	
begaring of Pathology, Seoul National University Sandang Hospital, 300 culint-uong, Bundang-ga, Seonghain-s, Gyeonggi 403-707, Republic of Korea 1 3	
BRAF (4%)	
14:20 - 15:05 45 Immunohistochemical principles: Autophosphorylation	
The technical test approach - post-analytical phase I 22-24 28	
15:05 – 15.25 20 Coffee Mutations associated 15:25 – 16:10 45 Improving the interpretation of the content of the con	
13.23 = 10.10 43 Initiational stock femiciples.	
i ne technical test approach - post-analyti <mark>cal phase t</mark>	
16:15 – 17:00 45 Immunohistochemical classification of broads Tribunation AVL	
tumoúrs Social arrangement (optional) Keglespil (Skittles) S	50
Exon 18 Exon 19 Exon 20 Exon 21	80
Thursday, September 21 st nucleotide-binding loop) Exon 19 Exon 20 (activation loop)	
08:15 - 09:00 45 Optimization of antibodies 45 ection, protocols and N8265 L858R (40-45%)	
controls (<1%) controls (<1%) (<1%) (<1%) A839T (×1%) (<1%)	
09:00 – 09:45 45 Immunolistochemical classification of the MV ^{L861Q} _{G863D}	
unknowf?@rimary tumourLZ47-part5fP) (40–45%)	
09:50 - 10:10 20 <i>Confee</i> ALA-7-1751 (ins P/S)	
10:10 – 10:40 30 Optimization of antibodies 1/4 selection, protocols and SN	
controls solition of the controls of the controls of the controls of the controls of the control	
unknown primary tumou 65752-part II	
11:35 – 12:05 30 Optimization of antibodies, selection, protocols and SN	



Lung cancer,

diagnosis and prediction.



exon 19 and an L858R mutation in exon 21 by immunohistochemistry

MV

SN

Program

10:45 - 11:30

11:35 - 12:05

45

30

Wodnoodov C	· · · · · · ·	neg oth	+	2+	3+	-	
Wednesday, S	epter	nder 20"	The state of the s		A AN A	9	
09:30 - 10:00	1000	Arrival, coffee					
10.00 10.5	15	Welcome and int	roduction		SN	E.	746-A750
	45	Immunohistoche	The second second				el-specific AB SPII
19-19-11-00			20 20 20 20 20 20 20 20 20 20 20 20 20 2	re-analytical phase I	ON		ci-specific AD 51 11
Oncogene 'drivers' in Adenocarcinoma	243.00	The state of the s	The second of the second of	(1) 10 10 10 10 10 10 10 10 10 10 10 10 10			
Unknown (32.5%)	45	Immunohistoche		LANGUA WAR TO THE REAL PROPERTY OF THE PARTY	ON		
	66 60			re-analytical phase II	A TOP OF THE SECOND		
1 <mark>2:00 -</mark> 12:45	45	Immunohistoche	mical principle	5.	MA AL	E.	746-A750
- Gene Mu	utation	The technical tes	t approach - a	nalytical phase I	4 4 6		
ROS1 (1%) 2:45 - 13:30 Gene Fu	usion 45	Lunch		ALLES ESTATEMENTS		Q C	el-specific AB SP11
F5B-RET (1.5%)	mplification 45	Immunohistoche	mical principle	S. S		The state of	
HER2 (20%)	E	The technical tes			MB	河 建 州。	
14:20 - 15:05	45	Immunohistoche	• •			Non-	
17.20 13.03	73	The technical tech	t approach - p	oct analytical phace I	SN		
Table 2 15:05 - 15.25 Siagnostic	power of m	tation جهوcific antibodies con	nparing with EGFR muta	tional status.			
15:U5 - 15.25 -	n specificani	ibadios L. FCEP m	utations	Concitivity (%)	Specificity (%)	PPV (%)	NPV (%)
15:25 - 16:10 Mutation					SN	11 V (%)	141 V (%)
	FR E/46_A/50	I de technical / tes	t ⁵ ars of Foach - po	ost-analytical phase II	96.1%	80.0%	99.0%
16:15 - 17:00	45	Immunohistoshe	micalitclassifica	ition of breast		92.3%	95.3%
			3 as positive	29.4%	99 A VL	100.0%	89.6%
17.00 - 19.00		Social arrangeme	tions in exon 19 ant (optional) -	- Keglespil (<u>Skittles</u>)	96.6%	85.0%	86.0%
		· Caona	2 as positive	40.3%	99.4%	96.2%	82.7%
Thursday, Sept		F Z L Score	3 as positive	16.1%	100.0%	100.0%	77.4%
08:15 - 09:00 Anti-EGF	FR L858R	Ontimization of a	ntihodies sele	ection, protocols and	50.0%	20.7%	07.00/
00.13 03.00		controls - breast	Thas posterves, sere	80.4%	50 5% 89.7%	30.7% 64.9%	97.0% 95.1%
00:00 00:45	45	Immunohistoche			100,0%/	100.0%	87.8%
09:00 - 09:45	45	THITHUHORISTOCNE itive predictive value: NPV ne	HIICAL CIASSIFICA Pative predictive value	t t	IVI V		
		itive predictive value: NPV ne	rtumour - par	TΙ			
09:50 - 10:10	20	Coffee				Cont	ents lists available at ScienceDirect Lung Cancer
10:10 - 10:40	30	Optimization of a	ntibodies, sele	ection, protocols and	SN	ELSEVIER journal homep	age: www.elsevier.com/locate/lungcan
		controls – unkno	wn primary tui	mours part I	SIN	Novel EGFR mutation-specific as	ntibodies for lung adenocarcinoma:
				<u>'</u>		Highly specific but not sensitive	detection of an E746_A750 deletion in

Immunohistochemical classification of the

Optimization of antibodies, selection, protocols and

unknown primary tumour - part II


Lung cancer,

diagnosis and prediction.



Program

Algorithm Wednesday, September 20th 09:30 - 10:00 Arrival, coffee Welcome and introduction **15**



08:15 - 09:00	45	Optimization of antibodies, selection, protocols [a] dontrols – breast tumours	$\mathbf{R}_{N}\mathbf{T}$
09:00 - 09:45	45	Immunotisto and the last of the	MV
		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls E antibown to imary tumours part I	SN
10:45 - 11:30	45	controls Furthermical classification of the unknown primary tumour – part II	MV
44.05.40.05		, ,	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CN

Lung Cancer



R mutation-specific antibodies for lung adenocarcinoma: cific but not sensitive detection of an E746_A750 deletion in



Lung cancer,

diagnosis and prediction.



Analysis

Program

Wednesday, September 20th

wednesday, se	pten	ibei 20	
09:30 - 10:00		Arrival, coffee	
	15	Welcome and introduction	SN
	45	Immunohistochemical principles:	ON
Oncogene 'drivers' in Adenocarcinoma		The technical test approach – pre-analytical phase I	014
Oncogene 'drivers' in Adenocarcinoma 11:05 11:50 RAS (35%)	45	Immunohistochemical principles:	ON
12.00 12.45	4=	The technical test approach – pre-analytical phase II	
12:00 - 12:45	45	Immunohistochemical principles:	MB
Gene Mutation		The technical test approach - analytical phase I Lunch	
ROSI (1%) 45 13 39 Gene Fusion KIFSB-RET (1.5%) 3 30 14 15 15 15 15 15 15 15 15 15 15 15 15 15	45 45	Immunohistochemical principles:	Table 1
HER2 (Ex)	45	The technical test approach - analytical phase	MB
14:20 - 15:05	45	Immunohistochemical principles:	
11.20 13.03	-15	The technical test approach - post-analytical phase I	SN
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochemical principles:	
		The technical test approach - post-analytical phase II	SN
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL
		tumours	AVL
17.00 - 19.00		Social arrangement (optional) – Keglespil (Skittles)	
Thursday, Septe	mbe	r 21 st 7	CD
08:15 09:00	45	Optimization of antibodies, selection, protocols and	$\cup R$
08.13	73	controls – breast tumours	SN
09:00 109:45	45	Immunohistochemical classification of the	MV
1		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
		controls – unknown primary tumours part I	SIV
1Tissue1se2tion	45	Immunohistochemical classification of the	MV
	200	unknown primary tumour – part II	1*1 V
11:35 – 12:05	30	Optimization of antibodies, selection, protocols and	SN




Lung cancer,

diagnosis and prediction.



Program





Lung cancer,

diagnosis and prediction.




Program

11:35 - 12:05

Wednesday, September 20th

45

30



controls - unknown primary tumours part I

Optimization of antibodies, selection, protocols and

Immunohistochemical classification of the

unknown primary tumour - part II

SN

MV

SN




Lung cancer,

diagnosis and prediction.



Program



SN




Lung cancer,

diagnosis and prediction.



Program





Lung cancer,

diagnosis and prediction.



Program

09:30 - 10:00		Arrival, coffee			
10: A L 1 1 C 1 C 1 C C C C C C C C C C	15	Welcome and introduction	SN		
	45	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON		
Oncogene 'drivers' in Adenocarcinoma	45	Immunohistochemical principles:	ON		
12:00 - 12:45	45	The technical test approach – pre-analytical phase II Immunohistochemical principles:			
12.00 - 12.43	45	The technical test approach - analytical phase I	MB		
ROSI (1%) 2:45 - 13:30 Gene Fusion	45 ^E	The technical test approach - analytical phase I		ALK	
HER2 (2.5) 3:30 11.15 - Gene Amplific	45	Immunohistochemical principles:	МП	ALK	
BRAF (4%) ALK (5%)		The technical test approach - analytical physical physica	MB	ALK	
14:20 - 15:05	45	Imeau Azohistochemical principeas 64	SN	ALK	
		The technical test approach - post-analytical phase I	J. (ALK	
15:05 - 15.25	20	Coffee			
15:25 - 16:10	45	Immunohistochemical principles. ML4	SN	ALK	
		The 1 textonical test approach - post minalytical phase II	511	ALK	
16:15 - 17:00	45	Impgunghistochemical classification of breastile	AVL	ALK	
		tumours		ALK	
17.00 - 19.00		Social ^A arrangement (optional) Ekeg lespil (<u>Skittles</u>)			
Thursday, Septe	embe	TFG TFG		ALK	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	CNI	ALK	
		controls – breast tumours Coiled-coil domain	SN	Tyrosine kina	se domain
09:00 - 09:45	45	Immunohistochemical classification of the	MV	,	
		unknown primary tumour – part I			
09:50 - 10:10	20	Coffee			
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN		
		controls – unknown primary tumours part I	311		
10:45 - 11:30	45	Immunohistochemical classification of the	MV		
		unknown primary tumour – part II	I'I V		
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN		



Lung cancer,


diagnosis and prediction.



RAS → MEK → ErK

Program

Wednesday, September 20th





Thursday, Sept	embe	er 21 st	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	
92 -60 -		controls – breast tumours	
09:00 - 0 9 :4 5 0 -	45	Immunohistochemical classification of the M'	γ
-100		unknown primary tumour – part I	
09:50 - 10:10	200	Coffee 30 40 50 60 70 79	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	N
Figure 2: Waterfall p	lot showing	controls — unknown primary tumours part I	0

Figure 2: Watertall plot snowing response to crizouling in patients with a specific action proof of the 3-1703. Copyright © 2010, MV Massachusetts Medical Society.) unknown primary tumour - part II

11:35 - 12:05 30

Optimization of antibodies, selection, protocols and



SN

Chromesome 2p

ON

MB

SN

SN

AVL

SN



Lung cancer,

diagnosis and prediction.




Program

Wednesday, September 20th

Wednesday, Septen	ibel 20	\mathcal{D}^{0}
09:30 - 10:00	Arrival, coffee	
10: 00 + 10: 15 15	Welcome and introduction	SN
10/13 45	Immunohistochemical principles:	ON
Oncome (delicant) in Adama continues	The technical test approach – pre-analytical phase I	ON
Oncogene 'drivers' in Adenocarcinoma 11:50 NAAS (35%) 45	Immunohistochemical principles:	ON
	The technical test approach – pre-analytical phase II	OIN
1 <mark>2:00 -</mark> 12:45 45	Immunohistochemical principles:	МВ
- Gene Mutation	The technical test approach - analytical phase I	טויו
ROSI (1%) Gene Fusion 45	Lunch	
HER2 (23) 3 : 3 - 14.15	Immunohistochemical principles:	МВ
BRAF (4%) MFT (4%)	The technical Dect exprison of the final visito phase NA	יוו
14:20 - 15:05 45	Immunohistochemical principles:	SN
	The technical test approach - post-analytical phase I	5.1
15:05 – 15.25 20	Coffee E6;A20 EML4 ALK	
15:25 – 16:10 45	Immunohistochemical principles:	SN
Detection of chromoso	က်မှု techni္ခြံချို့ test approach post-analytical phase II Immunohistochemical classification of breast	0
16:15 - 17:00 45		AVL
changes	tumours E2;A20 E17;A20 EML4 ALK	
17.00 - 19.00	Social argangement (optional) Keglespil (Skittles)	
Thursday, Septembe	r 21st KIF5B-ALK KIF5B ALK Colled-coil domain Tyrosine kinase domain	
LIVIL-7	Tyrodine kindoe demain	

Detection of fusion protein



08:15 - 09:00	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45 45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10 20	Coffee	
10:10 - 10:40	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30 45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and	SN



Lung cancer,

diagnosis and prediction.

Optimization of antibodies, selection, protocols and





Program

11:35 - 12:05


30

09:30 - 10:00		Arrival, coffee E (C) C	
10: 00 + 10 :15 1	. 5	Welcome and introduction ISH	SN
10:00 15 1 10 15 100 4	ŀ5	Immunohistochemical principles:	-ON-
		The technical test approach - pre-analytical phase IC	ON
Oncogene 'drivers' in Adenocarcinoma 11:05 11:50 Unknown (32:55) RASS (35%)	ŀ5	Immunohistochomical principles:	
VINIONI (JEEJ 9)		The technical test approach – pre-analytical phase II	np WIN d
12:00 - 12:45	ŀ5	Immunohistochemical principles:	-
- Gene Mutation		The technical test approach - analytical phase I	MB
ROS1 (1%) 45 - 13:30 Gene Fusion 4	ŀ5	Lunch	
KIFSB-RET (1.5%) HER2 (3) 3 3 4 14.15	ŀ5	Immunohistochemical principles	
BRAF (4%)		The technical test approach - analytical phase II	MB
14:20 - 15:05	ŀ5	Immunohistochemical principles:	
		The technical test approach - post-analytical phase I	SN
15:05 - 15.25 2	20	Coffee	
15:25 - 16:10 4	ŀ5	Immunohistochemical principles	CNI
Detection of chrom	<u> </u>	The technical test approach - post-analytical phase II Immunohistochemical classification of breast	SN
16:15 - 17:00 4	15 15	Immunohistochemical classification of breast	A //
changes		tumours	AVL
17.00 - 19.00		Social arrangement (optional) — Keglespil (Skittles)	
Thursday, Septem	nber	· 21 st	
08:15 - 09:00 ALK-	AL4/ALK Fusion	Optimization of antibodies, selection, protocols and	SN
		controls – breast tumours	MV
09:00 - 09:45 4	1 5	Immunohistochemical classification of the	IMIV
09:50 - 10:10 2		unknown primary tumour = part I Coffee	
	20		
10:10 - 10:40 3	80	Optimization of antibodies, selection, protocols and	SN
10:45 - 11:30 4	1 5	controls – unknown primary tumours part I Immunohistochemical classification of the	
10.45 - 11.50 - 4	ŀJ	unknown primary tumour – part II	MV
		ulikilowii priiliary turilour – part II	





SPEC ALK Dual Color Break Apart Probe hybridized to normal interphase cells as indicated





Lung cancer,

diagnosis and prediction.



Unknown

E17; A20

E2; A20

E15; A20

■ E18; A20


E14; A20

E20; A20 E13; A20

E6a/b; A20

Variant 3a/b

Program





Lung cancer,

diagnosis and prediction.



Unknown

E17; A20

E2; A20

E15; A20

E18; A20


E14; A20

E20; A20 E13; A20

E6a/b; A20

33%

Program






Lung cancer,

diagnosis and prediction.



Program






Lung cancer,

diagnosis and prediction.



Program






Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th



11:35 - 12:05

30

Arritment unohistochemistry SN

10715	L 1 N 00	45	Immunonist	achewicalibi	มูดมู	မြင္း essment marks for lu-/	ALK, run !	51 (OΝ			
Oncogen <u>e</u> (drivers' in Ad <u>e</u> nocarcinoma	4-	The technic	Concentrated antibodic	es n	Vendor	Optimal	Good		Poor	Suff. ¹	Suff. OPS ²
Unknown (32.5%)	drivers' in Adenocarcinoma	45	Immunonist	ocnemical pri	псууг	Leica/Novocastra	i I		ON			
			The technic	al test approa	ch +	pre⇔analytical p	hase II	[15	24	7	34%	22%
12:00	12:45	45	Immunohist	mAb clone 5Å4 OChemical pri	ncipl	3 Snosan	1		MB 24	,	34%	2270
	- Gene Mutatio	n	The technic	al test approa	ch 🗓	ThermoFisher analytical phase Dako	I		MID		<u> </u>	
ROS1 (1%) 12:45	- 13:30 Gene Fusion	45	Lunch	mAb clone ALK1	1	Cell Marque	0	0	0	3	-	-
1.3:30	Gene Amplific	45	Immunohist	<i>™</i> Hemi P FI3pri	ncii	<u>હ</u> ્યા Signaling	6	12	3	2	78%	94%
BRAF (4%)	EGFR (15%) — ALK (5%)		The technic	mAb clone OTI1A4	ch 13	ORIGENE	- 10	3	MB o	0	100%	100%
	- 15:05	45	Immunohist	antibodies					- 101			
			The technic	phosete approa	ch e	postnanalytical p	ha s e I	0	6	0	-	-
Detection	$ar{o}_{1}^{15} ar{o}_{0}^{25}$ fusio	20 n aro	_C offee	mAb clone 5A4		Maria da	0	0	1	0	-	
15:25	- 16:10	45		MAB-0281 Ochemical pri	ncipi	les:		T 0 5	SN 1			
0000	2000000000	20000	The technication	aviate out a popuro a	ch ±	Moster analytical p	hase I	I o i		0	-	

13.23 - 10.10	111111111111111111111111111111111111111	mAb 5A4	UPI	25.	i i	C	N 1			
000000000000000000000000000000000000000	The technic	A A Test zpoproac	ի <u>1</u>	Master Binanytical p	hase II	[0 5	1	0	-	Q-1
16:15 - 17:00 45		ተያርካውስት F Aal clas	sific	ation: of breast	О	¹ /	VL ⁰	0	-	
17.00 - 19.00	tumours Social arran	mab alk1 gement (option	ر اها	Dako - Keglesnil (S	o kittles) 0	1	8	-	-
Thursday, September		mAb clone ALK1 GA641	_	Dako	0	0	0	4	-	-65
08:15 - 09:00 45		mAb clone ALK1	7 S A	Ventana lection, protoco	ols and	-1	2	5	-	-
00.13	controls – b	r of antibodies, rmab clone sps rmab tumours	1	BioGenex	0	o S	N o	1	-	-
09:00 - 09 <mark>:45 </mark>	Immunohist	ල්ල්ල්ල්ල්ල්ල්ල්ල්ල්ල්ල්ල්ල්ල්ල්ල්ල්ල්	sific	ation of the	53	₁₂ N	1V 4	1	93%	100%
09:50 - 10:10 20	unknown pr Coffee	і́∰,ДГ,У _п і Ы́ І́́	- pa	irt I Ventana	1	0	1	0	-	-
10:10 -ALKO fusion 0	Optimizatio	mAb_clone oti1A4 i թ3նե-∂մ1ե i bodies,	słe	 @ctiofinetpl rotoco	ols¹ano	d 0 C	0	0	-	-
	controls - u	Total	y ₁₈ 5	ımours part I	72	43	N 43	31	-	
10:45 - 11 pmotein 45	Immunohist	Proportion	sific	ation of the	38%	23% N	V ^{23%}	16%	61%	




Lung cancer,

diagnosis and prediction.



Program






Lung cancer,

diagnosis and prediction.



Program



Lung cancer,

diagnosis and prediction.

PRELIMINARY




Gene Mutation

Gene Fusion

Gene Amplification - Unknown

KRAS (35%)






Lung cancer,

diagnosis and prediction.



Program





Lung cancer,

diagnosis and prediction.



Program

Wednesday, Se	pten	ibei 20		
09:30 - 10:00		Arrival, coffee		
1000 10:15	15	Welcome and introduction	SN	
	45	Immunohistochemical principles:	ON	
Oncogene 'drivers' in Adenocarcinoma		The technical test approach – pre-analytical phase I	ON	
Oncogene 'drivers' in Adenocarcinoma 11:05 11:50 KRAS (35%)	45	Immunohistochemical principles:	ON	
		The technical test approach – pre-analytical phase II		
12:45	45	Immunohistochemical principles: Kinase	МВ	ROS1
- Gene Mutati		The technical test approach - analytical phase 134 33		On the Park State of the Control of
ROS1 (1%)	45	Lunch		CD74-ROS1 (exon 32)
HER2 (-1)3:30 - 14:15 Unknown	45	Immunohistochemical principles:	MB	CD74-ROS1 (exon 34)
BRAF (4%) MET (4%)	4-	The technical test approach - analytical phase in		CD74-RO31 (exoli 34)
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase (income)	SN	EZR-ROS1
15.05 15.25	20	The teerinear test approach post analytical place		LZN NOSI
15:05 - 15.25	20	Coffee Immunohistochomical principles		LRIG3-ROS1
15:25 - 16:10	45	immunonistochemicai principies:	SN	Lilloo Hooz
16:15 - 17:00	45	The technical test approach - post-analytical phase II Immunohistochemical classification of breast		SDC4-ROS1 (exon 32)
16.13 - 17.00	45	tumours	AVL	Plane her legion with the mental it waste.
17.00 - 19.00		Social arrangement (optional) – Keglespil (Skittee)		SDC4-ROS1 (exon 34)
	_	-12		
Thursday, Septe	embe	r 21 st Kinase		SLC3A42-ROS1 (exon 32)
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	SN	
		controls – breast tumours	SIV	SLC3A42-ROS1 (exon 34)
09:00 - 09:45	45	Immunohistochemical classification of the	MV	18894140220
		unknown primary tumour – part I		TPM3-ROS1
09:50 - 10:10	20	Coffee		
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN	FIG-ROS1
		controls – unknown primary tumours part I	514	
10:45 - 11:30	45	Immunohistochemical classification of the	MV	
		unknown primary tumour – part II		
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CN	



Lung cancer,

diagnosis and prediction.




Program

11:35 - 12:05

30

Wednesday, September 20th



unknown primary tumour - part II

Optimization of antibodies, selection, protocols and



Lung cancer,

diagnosis and prediction.



Program


14:20 - 15:05

Wednesday, September 20th

45

~45

45



Lunch Immunohistochemical principles: MB

The technical perfection of futigod of RNA Immunohistochemical principles:

SN The technical test approach - post-analytical phase I

SN

15:05 - 15.25 Coffee 20 15:25 - 16:10 45 Immunohistochemical principles:

CD74-ROS1 (exon 34) SN

Detection of chromosomae technical test approach - post-analytical phase II 45 Immunohistochemical classification of breast

^{16:15 - 17:00} **changes** AVL tumours

Social arrangement (optional) 17.00 - 19.00

Thursday Sentember 21st

iliuisuay, Se		Mildse SLCSA42-ROSI (EXOII 52)	
08:15 - 09:00	45 ROS1	Optimization of antibodies, selection protocols and 34) controls – breast tumours	SN
09:00 - 09:45		Immunohistochemical classification of the HG-ROS1 unknown primary tumour – part I	MV
09:50 - 10:10	20	Coffee	
10:40 - 10:40	-	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30		Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CN




Lung cancer,

diagnosis and prediction.



Program





Lung cancer,

diagnosis and prediction.



Consider repeat


testing or testing

for other targets

including ROS1

fusion

Program





Lung cancer,

diagnosis and prediction.



Program

Wednesday, s	ocptc.	iibci 20	
09:30 - 10:00		Arrival, coffee	-!
10:00 - 10:15	15	Welconcardene uditivers' in Adenocar	суюта
10:15 - 11:00	45	Immunohistochemical principles:	ON
	Unknov	wnThe technical test approach – pre-analytical phase is	35%)
11:05 - 11:50	45	Immunohistochemical principles:	ON
		The tech <mark>nical test approach</mark> – pre-analytical phase II	ON
12:00 - 12:45	45	Immunohistochemical principles:	MB
		The technical test approach - analytical phase I	MD
12:45 - 13:30	45	Lunch	
13:30 - 14:15	45	Imm <mark>unohistochemical prin</mark> ciples:	MB
		The t <mark>echnical test approac</mark> h - analytical phase II	11D
14:20 - 15:05	45	Immu <mark>nohistochemical princ</mark> iples:	SN. Gene Mutation
		The technical test approach - post-analytical phase I	Gene Mutation
15:05 - 15.25	20	Coffee	
15:25 - 16:10	4509	Immunohistochemical principles:	SN - Gene Fusion
		The technical test approach - post-analytical phase II	Gelle Fusion
16:15 - 17:00	KIF5B-RE	T Immunohistoch <mark>emical class</mark> ification of breast	AVE Gene Amplification
		tumours	- Unknown
17.00 - 19.00		Social arrangement (optional) – Keglespil (<u>Skittles</u>)	- F Olikilowii
Thursday, Sep	tembe	er 21 ^{st)} EGFR (15%)	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	
00.13 - 09.00	45	controls - breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the	MV
09.00 - 09.43	73	unknown primary tum o ur – part I	1*1 V
09:50 - 10:10	20	Coffee	
10:10 - 10:10	c 30	Optimization of antibodies, selection, protocols and	
Nëar	tiĭtı	Formization of antibodies, selection, protocols and selection of antibodies, selection of antib	SN
10:45 - 11:30	45	Immunohistochemical classification of the	
	,	unknown primary tumour – part II	MV
11:35 - 12:0 5 110		Optimization of antibodies, selection, protocols and	
==:35		, opinization of antibodico, ocidenti, protocolo and	SN



Lung cancer,

diagnosis and prediction.



Program

Other lung carcinoma carcinoma e.s. squamous, 10

10:45 - 11:30

11:35 - 12:05

30

Wednesday, September 20th

09:30 - 10:00	Arrival, coffee	Next generation seq.
	15 Welcome and introduction	SN SIN SIN SIN SIN SIN SIN SIN SIN SIN S
10:15 - 11:00	45 Immunohistochemical principles	s: ON
Possible,	The technical test approach - p	re-analytical phase I
11 : ກິ່ງວັນລble 1 : 50 or definite	45 Immunohistochemical principles	
adenocarcinoma	The technical test approach – p Immunohistochemical principles	• •
Reflex	The technical test approach - ar	IVIB
12:45 -deti§i@30	45 Lunch	KRAS, EGFR, BRAF, PIK3CA, AKT1, ERBB2, PTEN, NRAS, STK11, MAP2K1,
13:30 – 14:15	45 Immunohistochemical principle:	ALK, DDR2, CTNNB1, MET, TP53, SMAD4, FBX7, FGFR3, NOTCH1, ERBB4, FGFR1, FGMtB
	The technical proacher ar	halytical phase JI
Moleculai	The technical test approach - po	
testing 15:05 - 15.25	Coffee	ost-analytical phase i
15:25 Besoke0	45 Immunohistochemical principles	Si
decision	The technical test approach po	SN ost-analytical phase II
16:15 - 17:00	45 Immunohistochemical classifica	ALM DET DOCT and AUDICI fucion transcerints, in addition to targets decigned
Patient is never or	tumours Ion AmpliSeq"RNA Fusion Lung Cancer Sequencer	ION HEDOTOR SOTWARE
Icng-time ex-emoker (MDT discussion or	Social arrangement (optional) -	- Keglespil (Skittles)
Thursday, Septer	mber 21 st Construct ubrary and prepare template NGS	fusion detection
08:15-09:00	45 Optimization of antibodies, sele	ction, protocols and SN
T	controls – breast tumours	

45	Optimization of antibodies, selection, protocols and	SN
	controls – breast tumours	511
45	Immunohistochemical classification of the unknown primary tumour – part I	MV
20	Coffee	
30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
45	Immunohistochemical classification of the unknown primary tumour – part II	MV

Optimization of antibodies, selection, protocols and



SN



Lung cancer,


diagnosis and prediction.



Program

or carres acy, c	opto.		K I	
09:30 - 10:00		Arrival, coffee	IN:	anoString
10:00 - 10:15	15	Welcome and introduction	SN	0
10:15 - 11:00	45	Immunohistochemical principles:	ON	
Possible,		The technical test approach – pre-analytical phase I	ON	
11:05bable 1:50	45	Immunohistochemical principles:	ON	
or definite adenocarcinoma		The technical test approach – pre-analytical phase II	OIV	
1 2:00 - 12:45	45	Immunohistochemical principles:	MB sandoning	
Reflex	Stel	The technical test approach - analytical phase I	, ,,5	
12:45 detigogo	Hypri	Automated Sample Immunohistochemical principles:		
13:30 - 14:15	45	Immunohistochemical principles:	MB	
•		The technical test approach analytical phase II		
14:20 - 15:05 Molecular	45	Immunohistochemical principles:	SN	
testing		The technical test approach - post-analytical phase I		
15:05, 15.25	20	Coffee		
15:25 Bespoke of decision	45	Immunohistochemidal pariciples !	SN	
by MDT		The technical test approach - post-analytical phase II		
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL	
Patient is never or		tumours 3		
Icng-time ex-smoker (MDT discussion or	\rightarrow	Social arrangement (optional) – Keglespil (Skittles)		
Thursday, Sept	tembe	Target 2: 2	Analysis Software	
08: request)	45	Optimization of antibodies, selection, protocols and		
		controls – breast tumours	SN	
09 00 09:45	45	Immunohistochemical classification of the	MV	
carcinoma		unknown primary tumour – part I		
၂ e g. squamçııs, 10	20	Coffee		
10.10 - 10.40	30	Optimization of antibodies, selection, protocols and	CN	
		controls – unknown primary tumours part I	SN	
10:45 - 11:30	45	Immunohistochemical classification of the	N/1) /	
		unknown primary tumour – part II	MV	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN	

Patient selection in lung cancer: Evolution over time





Program

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



Wednesday, Septe	mber 20 th T-cell	
09:30 - 10:00	Arrival, coffee	
10:00 - 10:15 15	Welcome and introduction	SN
10:15 - 11:00 45	Immunohistochemical principles:	ON
	The technical test approach - pre-analytical phase I	ON
11:05 – 11:50 45	Immunohistochemic <mark>al principles:</mark>	ON
10.00 10.15	The technical test approach - pre-analytical phase II	
12:00 - 12:45 45	Immunobistochemical principles:	MB
12:45 - 13:30 45	The technical test approach - analytical phase I +	
13:30 - 14:15 45	Immunohistochemical principles:	
13.30 - 14.13	The technical test approach - analytical phase II	MB
14:20 - 15:05 45		all recentor
1.120 10.00	The technical test approach - post-analytical phase I	ell receptor
15:05 – 15.25 20	Coffee	
15:25 - 16:10 45	Immunohistochemical principles:	CNI
	The technical test approach - post analytical phase Pro	antigen
16:15 - 17:00 45	Immunohistochemical classification of breast	AVL
17.00	tumours	/ \ \ -
17.00 - 19.00	Social arrangement (optional) – Keglespil (<u>Skit/les</u>)	
Thursday, September	er 21st and a second a second and a second a	
08:15 - 09:00 45	Optimization of antibodies, selection, protocols and	SN
	controls - breast tumours	
09:00 - 09:45 45	Immunohistochemical classification of the	MV
00.50 40.40	unknown primary tumour – part I	
09:50 - 10:10 20	Coffee	
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30 45	Immunohistochemical classification of the	
10.73 11.30	unknown primary tumour – partstāt c cell	MV
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and	SN



Program

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



Wednesday, Se	epten	nber 20 th T-cell	
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach - pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemic <mark>al principles:</mark>	ON
		The technical test approach - pre-analytical phase II	
12:00 - 12:45	45	Immunobistochemical principles:	MB
12.45 12.20	4 =	The technical test approach - analytical phase I +	
12:45 - 13:30	45 45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles: The technidal test approach - analytical phase II	MB
14:20 - 15:05	45		Luccontou
14.20 15.05	75	The technical test approach - post-analytical phase I	l reseptor
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochomical principles	
		The technical test approach - post analytical phase 11 ph	ntigen .
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL
		tumours	AVL
17.00 - 19.00		Social arrangement (optional) – Keglespil (Skittles)	
Thursday, Septe	embe	r 21 sterolizumab	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	
	_		SN
Predictive I	ma i	nohistochemical classification of the	MV
		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
		controls – unknown primary tumours part I	SIN
10:45 - 11:30	45	Immunohistochemical classification of the	MV
11 25 12 25		unknown primary tumour – parhstdlc cell	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN



Lung cancer,

diagnosis and prediction.




Program

Wednesday, September 20th

for the KEYNOTE-024 Investigators*

30

11:35 - 12:05




unknown primary tumour - part II

Optimization of antibodies, selection, protocols and

SN

Lung cancer,


diagnosis and prediction.




Kromogen (farvestof)

Visualiseringssystem (enzymer) Sekundært antistof Primært antistof

Antigen Cellens cytoplasma Cellekerne







Lung cancer,

diagnosis and prediction.



Program


Wednesday, September 20th


09:30 - 10:00	Kromogen (farv	estorival, coffee	
10:003- 10:15	15	Welcome and introduction	SN
-10.15 - 11.00	15	Immunohistochomical principles:	

11:05 11:50 **Tumor cells** 12:00 - 12:45

(TCs)

Tumor and immune cells (TCs and ICs)





Thursday, Se

12:45 - 13:30 13:30 - 14:15

14:20 - 15:05

15:05 - 15.25 15:25 - 16:10

16:15 - 17:00

17.00 - 19.00

08:15 - 0	9:	00
-----------	----	----

09:00 - 09:45	45	Immunohistochemical classification of the	MV
		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee Immunhistological staining for	or PDL
10:10 - 10:40	30	Coffee Immunhistological staining for Optimization of antibodies, selection, protocols and	CN
		controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the	NA\ /
		unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN
		· · · · · · · · · · · · · · · · · · ·	-51V

Lung cancer,





Program

Wednesday, Se	pte	mber 20 th	E1L3N antibody	SP142 antibody
09:30 - 10:00		Arrival, coffee		15/1 1 m. (a) 10 m. a. 1
10:00 - 10:15	15	Welcome and introduction	g	5N
10:15 - 11:00	45	Immunohistochemical principl	The second secon	NI SECTION OF THE PROPERTY OF
		The technical test approach –	pre-analytical phase I	
11:05 - 11:50	45	Immunohistochemical principl		ON
12:00 - 12:45	45	The technical test approach – Immunohistochemical principl	pigeranalytical phase II	A CONTRACTOR OF THE PARTY OF TH
12.00 - 12.43	43	The technical test approach -		4B
12:45 - 13:30	45	Lunch	a many cical pridace i	
13:30 - 14:15	45	Immunohistochemical principl	es:	AD.
	7	The technical test approach -		4B
14:20 -/15 :05	45	Immunohistochemical principl	A STATE OF THE PARTY OF THE PAR	100 μm
	4	The technical test approach -	ost-analytical phase I	
15:05 - 15.25	20	Coffee	£	
15:25 - 16:10	45	Immunohistochemical principt The technical test approach -	(2) 中央の大学をは、日本の大学を表現しています。 またいまたいできた。 などのはないできょうとうにより、	SN .
16:15 - 17:00	45	Immunohistochemical classific		通知
10.13	71	tumours		VL
17.00 - 19.00		Social arrangement (optional)	- Keglespil (Skittles)	
Thursday, Septe	mbe	21st	itive	
08:15 - 09:00	45	Optimization of antibodies, se	oction, protocole and	
08.13 - 09.00	73	controls breast tumours	Eguon, protocols and	N
09:00 - 09:45	45	Immunohistochemical classific	ation of the	1V
	X WILL	unknown primary tumour – pa		The same of the same of the same of
09:50 <u>- 10</u> :10	E. C. JANSKINS	Coffee		The same of the same
10:10 1mT0:40	30	Optimization of antibodies, sel		100 µm
10 15 11 20	4-	controls – unknown primary to		No. of the second secon
10:45 - 11:30	45	Immunohistochemical classific	IV.	1V ₁₁₇
11:35 - 12:05	30	unknown primary tumour – pa Optimization of antibodies, sel	action protocols and	
11.55 - 12.05	30	Optimization of antibodies, set	S	SN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON
ffa 영 통 나 11:50	45	Immunohistochemical principles:	ON
Results of randomised pl	nase III	tritle deciminat destrapiotoacibitored Giral forcad presed mon-	small-cell lung cancer (NSCLC).

12n00f-tr22in45nt	Dr 45		histoghemical prin	-	ORR	MBPFS (mont	ths)	OS (month	ns)
12:45 - 13:30	45	The tech <i>Lunch</i>	nical test approac	h - analytical phas	se I	Median	HR	Median	HR
¹ / ₃ :30 - 14:15	Pe mp rol		histexintenlical prin	cipłés%	45%	10.4	0.50	NR	0.60
			ini&#t&statappiloac</td><td></td><td>se I$^{26\%}$</td><td>М$oldsymbol{B}_{2.2}$</td><td>1.15</td><td>14.4</td><td>1.02</td></tr><tr><td>1142: 200d beyrsinds</td><td></td><td></td><td>histornemical prin</td><td></td><td>18%</td><td>4</td><td>0.79</td><td>12.7</td><td>0.61</td></tr><tr><td></td><td></td><td></td><td>nikavtest approac</td><td></td><td>l phase/1</td><td>$SN_{5.2}$</td><td>0.59</td><td>17.3</td><td>0.50</td></tr><tr><td>15:05 - 15.25</td><td></td><td>nabCoffee</td><td>Checkmate-017</td><td>No</td><td>20%</td><td>3.5</td><td>0.62</td><td>9.2</td><td>0.59</td></tr><tr><td>15:25 - 16:10</td><td></td><td></td><td>histockentical prin</td><td>icin es</td><td>19%</td><td>2.3</td><td>0.92</td><td>12.2</td><td>0.73</td></tr><tr><td>13.23 10.10</td><td>Atezoliz</td><td>umine tech</td><td>nical test approac</td><td>h ^Npost-analytical</td><td>l phase ÎI</td><td>SN_{2.8}</td><td>0.95</td><td>13.8</td><td>0.73</td></tr></tbody></table>						

1661 Eviation ORR, over 415 responsemente optisto; pergisal nela stational of; presist rogression-free survival; OS, overall survival; HR, hazard ratio; L1, first-line; L2, second-line umours

17.00 to 19.00 was used for inclassial barrangement (aptional) - PKSQ aspil (Skitter)t), OS and ORR (secondary end-points).

Thursdray, pseptiember 221

08:15 - 09:00 4	5	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45 4	5	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10 2	0	Coffee	
10:10 - 10:40 3	0	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30 4	5	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05 3	0	Optimization of antibodies, selection, protocols and	SN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

wednesday, s	eptember 20		
09:30 - 10:00	Arrival, coffee		
10:00 - 10:15	15 Welcome and introduction	n SN	
10:1 ^{5est} 11:00	45 Immunohistochemical pri Ventah៖ នាខ្លាំស្ការ test របូរស្រី	zd3 (2)pre-analyticabako 28-8 (3)	Ventana SP142 (4)
.1:05 - 11:50	45 Immunohistochemical pri	· ()N	
Developed as 2:00 - 12:45	The technical test approa 45 Immunohistochemical pri	Ifizumabr@NeroklyticaNipposeall inciples:	Atezolizumab
companion diagno 2:45 - 13:30	stic (Astrandenteenthnical test விற்றாற்கி 45 Lunch	MB adbohman)alytical pha(Beistol-Myers Squibb)	(Genentech)
3:30 - 14:15 Instrument	45 _{VEN} โกทุกษาคู่ประการและ pri The technical test สามารถ		VENTANA BenchMark
4:20 - 15:05	45ULTRAmmunohistochemical pri		ULTRA
5:05 - 15.25 5:25 - 16:10 5:25 - 16:10	20 Clone 名音名 (rabbit Clone 2)	2C3 (mouse Clone 28-8 (rabbit	Clone SP142 (rabbit
5:25 - 16:10	45 Immunohistochemical pri The technical test approa	monoclonal) SN ich - post-analytical phase II	monoclonal)
6:15 – 17:00 Compartment	45 Immunohistochemical cla Tum់ចុំដូច្នាប់មានទាំងក្នុង	assification of breast cell membrane Tumor cell membrane	Tumor cells and tumor-
7.00 – 19.00		onal) – Keglespil (<u>Skittles</u>)	infiltrating immune cells
Thu ଟିଞ୍ଚ ି ମ୍ଞ୍ଚିମ୍ୟ ୍ୟ		50% of tumor cells ≥1%; ≥5%; ≥10% of tumor	≥50% of tumor cells
8:15aigh (P-20:-00)	45 ^{≥25} %ର୍ମ୍ୟାନ୍ୟ ବ୍ୟୁଷ୍ଟିମ୍ପନ୍ (ର୍ଚ୍ଚ antibodie controls – breast tumours	es, selection, protocols and cells (7) SN	or ≥10% of tumor area
9:00 - 09:45	45 Immunohistochemical cla unknown primary tumour		
9:50 - 10:10	20 Coffee		
0:10 - 10:40	30 Optimization of antibodie controls – unknown prima	s, selection, protocols and SN ary tumours part I	
0:45 - 11:30	45 Immunohistochemical cla unknown primary tumour	MV	
.1:35 - 12:05	. ,	s, selection, protocols and	

Lung cancer,

diagnosis and prediction.



Program

Lung Cancer 2

• g. a					
Wednesday,	Septen	nb lea n zo ehof	Ventana	Dako	Dako
09:30 - 10:00		Strainain of the	SP263	22C3	28-8
10:00 - 10:15	15	Welcome and intro		THE SECONDARY PROPERTY.	SNOWNANDAND
10:15 - 11:00	45	Immurohistochen	TO A REAL PROPERTY OF THE PROPERTY AND PARTY AND PARTY.	The East of the	On the sale
			approach - pre-anal	ytical phase I 🤍	ON
11:05 - 11:50	45	Immunohistochen	NO. THE PARTY OF T		ON
		The technical test	approach - pre-anal	ytical phase II	Olympia Carrie Garage
12:00 - 12:45	45	Immurohistochem	The state of the s	MANAGE TO SERVE	MB
			approach - analytica	l phase I	
12:45 - 13:30	45	Lunch			F. War
13:30 - 14:15	45	Immurohistochem		A X X	MB
			approach - analytica	l phase II	BOWNESS TO THE
14:20 - 15:05	45	Immurohistochem	The state of the s	DV 17	SN
15.05 15.05			approach - post-ana	lytical phase I	
15:05 - 15.25	20	Coffee			
15:25 - 16:10	45	Immurohistochem		Lotte Care and Art I	SN
16.15.17.00	4=		approach - post-ana	COLUMN TRANSPORT OF THE PROPERTY OF THE PROPER	(6.74.1.4.3) A. S.
16:15 - 17:00	45		nical classification of	breast	AVL
17.00 10.00		tumours	ot (antiqual) Kaala	and Activities	Mary 1
17.00 - 19.00			nt (optional) – Kegle	espii (<u>Skitties</u>)	55 p 9 884
Thursday, Sep	otembe	r 21 st	#100.00 PM - 700.00 PM		Section and the organization of the section of the
08:15 - 09:00	45	Optimization of ar	ntibodies, selection,	protocols and	SN
		control - breast t	tumours		SIV
09:00 - 09:45	45	Immunohistochem	nical classification of	the/	MV
		unk nowh/p rimary	tumour – part I		
09:50 - Plip Grid I in Girst January	10, 2017; DOI: 2:0 /1078-0				
10 Cincer Therapy: Cinia 40	30	Optimizer on of an	ntibodies, selection,	protocols and	SN
Agreement between Prog	grammed Cell E	oeacontrois unknow	n primary tumours	part I	

10 Lia ក្នុង Diapnos nc Assays acros ម្តី dultiple Immunohistochemical classification of the Protein Expression Cutoffs in Non-Small Cell

11 Maria D. A. Alan Sterpe², Anita Midha¹, Crais Oct. Rebelatto Stell Walker Optimization of antibodies, selection, protocols and

ünknown primary tumour – part II

MV

SN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

Thursd	lay, Septe	mber	21 st	60	8 10 80 90
17.00 - 3	19.00		Social arrangement (ptional) - Reglespil (Stattles)	150	\(\rho^2\) \(\frac{19}{9}\) \(\rho^2\) \(\rh
10.13 -	17.00	43	tumours 0	AVL	
16:15 - 3	17:00	45	The technical test approach - post-analytical phase II Immunohistochemical classification of breast		 a transfer
15:25 -	10:10	45	Immunohistochemical principles:	SN	_
15:05 - 15:25 - 15:25 - 15:25	15.25		Coffee		
	on by bins (all sai	moles	The technical test approach - post-analytical phase I	J.,	
14:20 - : Figure 3.	15:05	45	Immunohistochemical principles:	SN	
			The Rechnical test approach - analytical phase II	MB	
13:30 -		45	Immunohistochemical principles:	MD	
12:45 -	13:30	45	Lunch		,
12.00	12.75	75	The technical test approach - analytical phase I	MB	■ Dako 28-8 total (<i>n</i> = 493)
12:00 - 1	12.45	45	The technical test approach – pre-analytical phase II Immuno is to chemical principles:		■ Dako 22C3 total (<i>n</i> = 493)
11:05 -	11:50	45	Immunohistochemical principles:	ON	■ Ventana SP263 total (<i>n</i> = 493)
	==		The teclatical test approach – pre-analytical phase I	J1 1	
10:15 -	11:00	45	Immunohistochemical principles:	ON	
10:00 -	10:15	15	Welcome and introduction	SN	
09:30 -	10:00		Arrival, coffee		
		•			

08:15 - 09:00	45	Optimization of antibodies, selection eprotacel spender	ntage staining bin (%)
		controls – breast tumours	SIN
09:00 - 09:45	45	Immunohistochemical classification of the	MV
		<u>unknown</u> primary tumour – part I	
09:50 - 10:10	78-0423.CCR-16-2375	Coffee	

Cancer Therapy: Clinical	4 0 4 0	
10:10	- 10:40	30
Agreement be	tween Programm	ed Cell Death
Ligand-1 Diagr	ostic Assays acro	ss Multiple
D., 41:0 F.4 E.		c 4 🖽

Protein Expression Qutoffs in Non-Small

Marianne J. Ratcliffe¹, Alan Sharpe², Anita Midha¹, Craig Barker², Marietta Scott², Paul Scorer², Hydram Al-Masri³, Marion C. Bebelatto⁴, and Jill Walka² **30**

Clinical Pather nization of antibodies, selection, protocols and controls - unknown primary tumours part I

Immunohistochemical classification of the unknown primary tumour – part II

Optimization of antibodies, selection, protocols and

SN

MV

SN



Lung cancer,

diagnosis and prediction.



Program	N. 2673	PRELIMINARY
Wednesday, So	epten	nber 20 th
09:30 - 10:00		Arrival, coffee
10:00 - 10:15	15	Welcome and introduction SN
10:15 - 11:00	45	Immunohist chemical principles
Cyto	loa	The technica approach – pre-analytical hase I
11:05 - 11:50	45	The technical principles: Immunohistecthal minar principles: Periferal tumor The technical test approach - pre-analytical phase II
		The technical test approach – pre-analytical phase II Immunohistochemical principles:
12:00 - 12:45	45	
		Ine technical testilapping ach - analytical phase I
12:45 - 13:30	45	Lunch Bronchial lavage, Course needle
13:30 - 14:15	45	Immunohistochism的 principles: biopsi MB
14.20 15.05		The technical test approach - analytical phase III
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach post applytical phase I
15:05 - 15.25	20	The technical test approach - post-analytical phase I Coffee
15:25 - 16:10	45	Immunohistochemical principles:
13.23 - 10.10		
16:15 - 17:00	45	Immunohistochomical classification of broast
10.15		tumours
17.00 - 19.00		Social arrangement (ക്രിസ്റ്റ് സ്പ്രേട്ട് eglespil (Skittles)
Thursday, Sept	embe	r 21st
08:15 - 09:00	94	Optimization of antibodies, selection, protected and SN
		controls – breast tumours
09:00 - 09:45	45	Immunichistochemical classification of the MV
		unknown primary, เมเชอนเดืองเดือง I
09:50 - 10:10	20	Coffee M from metastasis suspekte
10:10 - 10:40	30	Optimization of a ntibodies erselection protocols and SN
		controls – unknown primary tumours part I
10:45 - 11:30	45	Immunohistochemical classification of the
11 25		Ourknown primary tumour – part II Operabel 30%
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and



Lung cancer,

diagnosis and prediction.



Program

Wednesday September Spanning Spannin			
10:00 - 10:15	Wednesday, Sep	emBeragotArticle	
10: Paired: Comparison of Month Interchnication (Specification of Specification (Specification of Specification (Specification of Specification of Specification (Specification of Specification of Specification of Specification of Specification (Specification of Specification of	09:30 - 10:00	Arrival, coffee	
and Histologic Spec The ASP Fight F3 Manifolding residual phase I 11:0 Ling Assessed With Phase Fight F3 Manifolding residual phase II 12:00 - 12:45 PDSL1 Indicated phase II Prevaint of the technical test approach phase II 12:45 - 13:30 PDSL1 Indicated Part of the technical test approach phase II 13:30 - 14:15	10:00 - 10:15 1	Welcome and introduction	SN
and Histologic Specified of the first Plant Pla	10: Paired: Comparis	on of MD-distox penession inconsesy to logic	ON
12:00 - 12:45 PUSL Imhaudats tiphen (Tall Pkinciples: The technical test approach photo Conclusion: PD-L1 assessment is feasible on cytologic mate with the tested assays using cutoffs for positivity similar to the unch standard for standard standar	and Histologic S	pectheenshipfohtestyppingashiciees-inalytieal phase I	ON
12:00 - 12:45 PUSL I Inhaudakschafta Drinciples: The technical test approach - analytical phase I Conclusion: PD-L1 assessment is feasible on cytologic mate with the tested assays using cutoffs for positivity similar to the unch of the technical test approach - analytical phase II 14:20 - 15:05	Lung Assessed	With the technical test approach — pre-analytical phase II	ON
12:45 - 13:30 Birgit G. Slot Manuschier Standard Conclusion: PD-L1 assessment is feasible on cytologic materials of the conclusion: PD-L1 assessment is feasible on cytologic materials of the conclusion: PD-L1 assessment is feasible on cytologic materials of the conclusion: PD-L1 assessment is feasible on cytologic materials of the conclusion: PD-L1 assessment is feasible on cytologic materials of the conclusion: PD-L1 assessment is feasible on cytologic materials of the cyto	12·00 = 12·45 PM	ll I 11 Hours a Alista Alla ann 1821 Deineinles	MP
13:30 - 14:15 45	Rivait G. Ska	The technical test approach - analytical phase I	IVID
13:30 - 14:15 45	12:45 - 13:30 High G. 5.4	Lunch with the tested:	assays using cutoffs for positivity similar to the
The technical test approach - analytical phase II 14:20 - 15:05 45	13:30 - 14:15 4	Immunohistochomical principles:	
The technical test approach - post-analytical phase I 15:05 - 15.25		The technical test approach - analytical phase II	בויים
15:05 - 15.25 20 Coffee 15:25 - 16rABLE 3. IHC 45 hing brown primary large process of PD-L1 Positive year high exception process of PD-L1 Positive year high exception process analytical phase II 16:15 - 17:00 45 Immunohistochemical colors sirication of the second process of PD-L1 IHC 22C3 pharm Dx tumours 17.00 - 19.00 crall agreement Positive percent agreement Positive percent agreement Positive percent agreement Positive percent agreement Social arrangement (optional) (26 Kleglespil (Skittles) (94 (87-98) 100 (96-100) 93 (86-97) 100 (96-100) 93 (86-97) 100 (96-100) 93 (86-97) 100 (96-100) 93 (86-97) 100 (96-100) 93 (86-97) 100 (96-100) 93 (86-97) 100 (96-100) 100 (14:20 - 15:05 4	·	SN
15:25 - 16 ABLE 3. IHC Staning Enterorment Statistics for Different Thresholds of PD-L1 Positive yeechnical test approach - post-analytical phase II 16:15 - 17:00	15.05.15.05	• • • • • • • • • • • • • • • • • • • •	
Thresholds of PD-L1 Positive yeecnnical test approach - post-analytical phase II 16:15 - 17:00			
PD-L1 IHC 22C3pharmDxtumours 17.00 - 19.00erall agreement Positive percent agreement Social arrangement (optional) (76 Kleglespil (Skittles) 94 (87-98) 100 (96-100) Thursday: September 1st 89 (81-94) 93 (86-97) 08:15 - 09:00 45 Optimization of antibodies is selection up for to coles ain dells PD-L1 IHC 28-8 pharmDx controls - breast tumours 95 (89-98) 90 (81-94) 09:00 - 09: Asitive percent greement mmunohistochemical classification of their (83-95) MV 79 (70-87) 90 (81-94) Negative percent agreement pharmony (North our - part I 98 (93-100) 95 (88-98) 09:50 - 10: 10 lules are repre20d as partition of antibodies, selection, protocols and controls - unknown primary tumours part I 10:45 - 11:30 45 Immunohistochemical classification of the unknown primary tumour - part II 11:35 - 12:05 30 Optimization of antibodies, selection, protocols and on the unknown primary tumour - part II 11:35 - 12:05 30 Optimization of antibodies selection protocols and optimization of antibodies, selection protocols and optimization of antibodies and optimization	15:25 – 16;ABLE 3. IHC st. Thresholds of PD	hing ហែយេអាខារ៉ាទីរូលសិទ្ធាហទិត្តៀស្រាំបូអ៊ីរ៉ូងខ ថៃ With Histologic Sample: _1 Po sitiv eytechnical test approach - post-analytical phase II	s by Agreement Statistics for Different
PD-L1 IHC 22C3pharmDxtumours 17.00 - 19.00erall agreement			Cutoff $\geq 50\%$ Positive Cells
17.00 - 19.00 Grall agreement Social arrangement (optional) (76 Reglespil (Skittles) Positive percent agreement 80 (70-87) 100 (96-100	PD-L1 IHC 22C3pl	_{rmDx} tumours	
Thursday) September 21st 89 (81-94) 93 (86-97) 08:15 - 09:00	17.00 – 19.00 erall agreemen	Social arrangement (optional) (76 Keglespil (Skittles)	
$08:15-09:00 \textbf{45} \text{Optimization for antibodies} \\ \text{PD-L1 IHC 28-8 pharmDx} \\ \text{Controls - breast (19-3)} \\ \text{Oyerall agreement} \\ \text{Optimization for antibodies} \\ \text{Optimization of the less since the programmed cell (83-95)} \\ \text{Optimization of antibodies} \\ \text{Optimization of antibodies} \\ \text{Optimization of the less since the programmed cell death ligand-1} \\ \text{Optimization of antibodies} \\ \text{Optimization of antibodies} \\ \text{Optimization of the less since the ligand-1} \\ \text{Optimization of antibodies} \\ \text{SN} \\ \text{Optimization of antibodies} \\ \text{Optimization of antibodies} \\ \text{SN} \\ \text{SN} \\ \text{SN} \\ \text{SN} \\ \text{Optimization of antibodies} \\ \text{SN} \\ S$			
Overall agreement Oy:00 - 09:45 tive percent 45 eemei Immunohistochemical classification of the (83-95) Negative percent agreement known primary (tumour - part I 98 (93-100) O9:50 - 10:10 lues are repre20d as profiles. CI. 10:10 - 10:40 indicates configure integral. IHC optimization of antibodies, selection, protocols and controls - unknown primary tumours part I 10:45 - 11:30 45 Immunohistochemical classification of the unknown primary tumour - part II 11:35 - 12:05 30 Optimization of antibodies, selection, protocols and Unknown primary tumour - part II	08:15 - 09:00 4	Ontimization in the anti-honding lisselection of uniform of colorising the	Cutoff ≥ 10 % positive cells
09:00 – 09:45 itive percent 45 eeme Immunohistochemical classification of the (83-95) Negative percent agreement known primary (40m) our – part I 98 (93-100) 09:50 – 10:10 lues are repre 20 d as profite 6 CI. 10:10 – 10:40 indicates confidence interval: IHC immunohistochemistry: PD-L1 programmed cell death ligand-1 snown primary tumours part I 10:45 – 11:30 45 Immunohistochemical classification of the unknown primary tumour – part II 11:35 – 12:05 30 Optimization of antibodies, selection, protocols and Unknown primary tumour – part II	PD-L1 IHC 28-8 pr Overall agreemen	ontrois – breast tymours	
09:50 – 10:10 lues are repre 20 das p Coffee CI. 10:10 – 10:40 indicates configure interval. LHC immunohistoshemistry: PD L1 programmed cell death ligand-1 and controls – unknown primary tumours part I 10:45 – 11:30 45 Immunohistochemical classification of the unknown primary tumour – part II 11:35 – 12:05 30 Optimization of antibodies, selection, protocols and	Overall agreemen		JU (01-J 1)
10:10 – 10:40 indicates configure interval: IHC immunohistochemistry: PD LI programmed cell death ligand-I sand controls – unknown primary tumours part I 10:45 – 11:30 45 Immunohistochemical classification of the unknown primary tumour – part II 11:35 – 12:05 30 Optimization of antibodies, selection, protocols and	09:00 - 09:45 titive percent		MV 79 (70-87)
controls – unknown primary tumours part I 10:45 – 11:30 45 Immunohistochemical classification of the unknown primary tumour – part II 11:35 – 12:05 30 Optimization of antibodies, selection, protocols and	09:00 - 09:45 titive percent Negative percent	greem@hknown primafy(@mnour – part I 98 (93-100)	MV 79 (70-87)
10:45 – 11:30 45 Immunohistochemical classification of the unknown primary tumour – part II 11:35 – 12:05 30 Optimization of antibodies, selection, protocols and	09:00 - 09:45 titive percent Negative percent Negative percent	greemuhknown prima程y(他桁our – part I 98 (93-100) d as p Goffee , CI.	MV 79 (70-87)
unknown primary tumour – part II 11:35 – 12:05 30 Optimization of antibodies, selection, protocols and	09:00 - 09:45 titive percent Negative percent Negative percent	greem@hknown primary(&@mour – part I 98 (93-100) d as p@ffee CI. nce interval: JHC. immunohistochemistry: PD-L1 programmed cell death ligand-1 and Optimization of antibodies, selection, protocols and	MV 79 (70-87) 95 (88-98)
11.35 – 12.05 30 Ontimization of antibodies selection protocols and	09:00 - 09:45 titive percent Negative percent 09:50 - 10:10 lues are repre 10:10 - 10:40 indicates confidence in the c	greem@hknown primary(&@Mour – part I 98 (93-100) Ad as profile of CI. Controls – unknown primary tumours part I Controls – unknown primary tumours part I	MV 79 (70-87) 95 (88-98)
	09:00 - 09:45 titive percent Negative percent 09:50 - 10:10 lues are repre 10:10 - 10:40 indicates confidence in the c	greem@hknown primary(@mnour – part I 98 (93-100) Id as profitee, CI. Id as profitee, CI. Id as profitee, CI. In order interval: IHC, immunohistochemistry: PD LI, programmed cell death ligand-1 and controls – unknown primary tumours part I Immunohistochemical classification of the	MV 79 (70-87) 95 (88-98)

Lung cancer,

diagnosis and prediction.



Program

Wednesday No September a 20th control

31/08/2019 13.01

09:30 - 10:00 10:00 - 10:15 10:15 - 11:00



Arrival coffee

Info▼ Modules▼ Assessments Protocols Controls Events▼ Login

11:05 - 11:50

12:00 - 12:45

12:45 - 13:30 13:30 - 14:15

14:20 - 15:05

15:05 - 15.25

15:25 - 16:10

16:15 - 17:00

17.00 - 19.00


Thursday, Se

08:15 - 09:00

09:00 - 09:45

09:50 - 10:10

10:10 - 10:40



IHC for PAX8 in two laboratories: Lab 1 (A/C): Optimal results in Fallopian tube and Renal clear cell carcinoma. Lab 2 (B/D): Insufficient result in same tissues, especially characterized by false negative reaction in the neoplastic cells of the Renal clear cell carcinoma.

Results - Run 56, C5

9-Jul-2019

The results for the runs 56 and C5 are now available on the website. Individual results can be seen after logging in.

All news

10:45 - 11:30

11:35 - 12:05

partification of anaboutes, selection, protocols and

6th Academy of Diagnostic
Immunohistochemistry
9-11 Oct 2019: Krakow, Poland
4th NordiQC Conference on Applied
Immunohistochemistry

2-5 Jun 2020: Aalborg, Denmark

Events

NordiQC Workshop in Diagnostic Immunohistochemistry

2-4 Oct 2019: Aalborg, DK

Run 57, B28, H16, C6
Protocol submission deadline
4 Sep 2019
Slide circulation
10 Sep 2019
Slide return deadline
11 Oct 2019
Publication of results
6 Dec 2019

Questions

Check out our <u>FAQ</u> (Frequently asked questions) or contact us



Lung cancer,

diagnosis and prediction.



Program

	Table 3. Assessment marks for IHC assays and antibodies run C5, PD-L1 (lung	Assessm
Wednesday,	, Sept ce-IVD / FDA	PD-
09:30 - 10:00	approved n Vendor Optimal Good Bol NOI CICK Suff. OPS	
10:00 - 10:15	rmAb clone \$P263, 740- 1549073 Welcome and 6 introduction 12 2 2 SN 88% 93%	
10:15 - 11:00	4.5 TMAb clara SP263 37 SP263 37 SP263 37 SP263	
	rmAb clinertechnical test approach - pre analytical phase I	
11:05 - 11:50	45 ^{4905*} Immunohistochemical principles: rmAb clone SP263, 790 4905 The technical test approach – pre analytical phase II ON 92% 92%	
12.00 12.45		
12:00 - 12:45	4.5 nAb cldmansunohistochemical tost approach - appropriate phase in the second second seco	
12:45 - 13:30	mAb clohe echnical test approach - analytical phase I 4.3 harm DX FKEP5 9 Dako/Agilent 2 2 1 4 44% -	
13:30 - 14:15	4. harm Dine 22C3 harm Dine ohisto che அர்கு leprinciples: 3 MB	
	rmAb clinestechnical test approach - analytical phase II	
14:20 - 15:05	*Antibodies ¹⁰ for IHC TPS score*	
	laboratory developed PD-L1 assays, n Vendor Optimal Good Bassays,	
15:05 - 15.25	2(concentrated 1. Placenta See section for control	S
15:25 - 16:10	4 antibodies 2-3. Tonsil See section for control. MAb clone 2263 August 11 20 1260 August 2404 7404 7404	5
	mAb clone 22C3 1010 C42 Dako/Ağilent 11 20 Nscic 142 Dako/Ağilent 11 20 Ns	
16:15 - 17:00	45 _{mAb} classification of breast 5. NSCLC AV 67%; <1%100%	
	rmAb clone 28-8 4 Abcam 1 2 6. NSCLC 1 Low; ≥1-49%	
17.00 - 19.00	Social arrangementa(aptional) - keglespil (Skittles) Low; ≥1-49% / High ≥	:50%**
Thursday, Sep	ptember 2 1 Seta Colphation 1 9. NSCLC 3 Excluded (too few turn	our cells)
08:15 - 09:00	10. NSCLQ High; ≥50%	F00/ **
00.13 - 09.00	45 _{mAb c} Optimization of 8 millionics, selection, protocols1.a.md 5N -Low; ≥1-49% / High ≥	
00.00 00.45	rmap Bargu e. 3.3 3. 4.3 Norac Biosne 3	.50 70
09:00 - 09:45	Peady-To-lice	
09:50 - 10:10	antibodies OPS ²	
10:10 - 10:40	30mAb @ptiprization of antibodies, selection, protocols and	
10.10 - 10.40		
10.45 11.20	RMA-0732	
10:45 - 11:30	4.5 Immunohistoginemical classification of the 17 17 Proportunknown primary tumour – part II 51% 29% 10% 10% 80%	
11.05 10.05		
11:35 - 12:05	Optimization of antibodies, selection, protocols and SN	

ment Run C5 2019 D-L1 (lung)





Program

11:35 - 12:05

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.




Assessment Run C5 2019 PD-L1 (lung)

SN


10:00		T.I.I. 2. A	1 6 7116		5 14 (1		alac	,	
10:00	Wednesday,	Sept ce-IVD / FDA	narks for IHC assays and antibodie	s run C5, Pi	D-L1 (lu	ing) IHC			0.55
10:15 - 11:00		PD-L1 assays		Optimal	Good	Borderline	Poor	Suff. ¹	Suff. OPS ²
11:05 - 11:50 45905* Immunohistochemical principles: mab clone 22:3 12:00 - 12:45 45nab cdimmunohistochemical principles: mab clone 22:3 12:45 - 13:30 13:30 - 14:15 45nab cdimmunohistochemical principles: mab clone 22:3 mab clone 22:3 14:00 - 15:05 45nam d clone 22:3 45nam	10:00 - 10:15	1 1 1 1 1 1 1 1 1 1	and 6 introderation	12	2	2	SN	88%	93%
11:05 - 11:50	10:15 - 11:00						Ю	-	-
12:00 - 12:45	11:05 - 11:50	rmAb clone \$p. 162,741! 4!¾905 ⁵ Immunohi	<u>I</u> cai test approach – pro istochemical principles	e analyti :	ical pr	ase i	-	-	-
pharmby skeps chnical test approach - analytical phase I 44% 13:30 - 14:15 13:30 - 14:15 45 pharmby skeps of 9 Dako/Agilent 2 2 1 4 44% 13:30 - 14:15 14:20 - 15:05 45 pharmby skeps of 9 Dako/Agilent 2 2 1 4 44% 13:30 - 14:15 14:20 - 15:05 45 pharmby skeps of 9 Dako/Agilent 2 2 2 1 4 44% 13:30 - 14:15 14:20 - 15:05 45 pharmby skeps of 9 Dako/Agilent 2 2 2 1 4 44% 13:30 - 14:15 14:20 - 15:05 45 pharmby skeps of 9 Dako/Agilent 2 2 2 1 4 44% 13:30 - 14:15 45 pharmby skeps of 9 Dako/Agilent 2 2 2 1 4 44% 13:30 - 14:15 45 pharmby skeps of 9 Dako/Agilent 2 2 2 1 4 44% 14:30 - 15:05 15:05 - 15:05 15:05 - 15:05 26 pharmby skeps of 9 Dako/Agilent 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					icalloph	ase II	ŌN	92%	92%
12:45 – 13:30 13:30 – 14:15 4	12:00 - 12:45	4.5 nAb cld สามาณมาOhi	istochemical principles	: ₁₇	5 shase	-	₩В	92%	92%
14:20 - 15:05 4. Spharm Month	12:45 - 13:30	4 Ֆրharm [🗓 🖍 🗸 🗗 🗸 🤊 🗸 🗸 🗸 🗸 🗸 🗸 🗸 🗸 🗸 🗸 🗸 🗸 🗸	9 Dako/Agilent	2	2	1	4	44%	-
14:20 - 15:05 4 pharmity \$6005 Antibodies of the microl property of the manufacture of the microl property of t	13:30 - 14:15				-	-	МВ		
Antibodies of for laboratory developed 1. Placenta 1.	14.20 15.05	rmAb clldQ8T@CNNI	Ical test approach - and lictochemical principles	alytiçal p	nase	II Tissue co	ontrols	1110	. TPS score
15:05 - 15.25 15:25 - 16:10 2	14:20 - 15:05	Antibodies ¹⁰ for						See	e section for o
Thursday, Septem Thursday, S	15:05 - 15.25	2(PD-L1 assays, concentrated		Optimal	Good	2-3. Tons Borderline NSCLC	sil Poor	Suff. ¹	e seoglion for o
45 Immunohistochemical classification of breast 7. NSCLC AV 67% Low; ≥1.00 17.00 - 19.00 Thursday, Septem Der 21 1	15:25 - 16:10		ical test approach - no	st-analyt	20 ical n			74%No;	; <1%4%
17.00 – 19.00 Thursday, Septem ber 1 Zeta Corporation 1 Nordic Biosite 1	16:15 - 17:00	45 Immunohi	istochemical classificat	ion of b	reast	7. NSCLC	Δ\/	67% ^{Low}	v; ≥1-49 <mark>% /</mark>
Thursday, Septem ber 21st 1 Zeta Corporation Nordic Biosite 1 - 11: NSCLC 3 - Low; ≥1-2 Low; ≥1-	17.00 - 19.00	rmAb clone 28-8 Social arra	•	Keglest	oil ² (<u>S</u>			-) Exc	uded (too fe
08:15 - 09:00 45 Optimization of antibodies, selection, protocols and spiagomics SN - High; ≥50 SN - High; ≥5	Thursday, Sep		1 Zeta Corporation1 Nordic Biosite		-	11. NSCL	.c 3	- Low	v; ≥1- 4 9% ×
controls - bréast tumours rmAb BSR90 trols - bréast tumours 1	08:15 - 09:00	4.5 _{mAb cl} Optimizati	ion of antibodies, selec	ton, pr	otoco		_		
	09:00 - 09:45	rmAb BSR90 TOIS —	-breast tumours istochemical classificat	ion of th	- he₁	-	- MV	-	-
Ready-To-Use n Vendor Ontimal Good Borderline Poor Suff 1 Su	03100 03115		· - ·			Rorderline		Suff 1	Suff.
09:50 - 10:10 2(antibodies	09:50 - 10:10	2 (antibodies		-	-		-		OPS ²
THE THE THEORY SELECTION DEPOLATION IN THE RESERVE AND THE RES	10:10 - 10:40	30mAb QQIPZIPRZZZZZZZZZZ	ion of antibodies, selec	ton, pr	otoco		ÇVI		-
rmAb cocontends — unknowmh primary tumours part. I		KMA-0/32				-		-	-
10:45 – 11:30 45 Immunohistochemical classification of the 17	10:45 - 11:30	45 _{lotal} immunohi			he ₅₁	17	₩V		
Proportianknown primary tumour – part II 51% 29% 10% 10% 80%			primary tumour – part	1 51%	29%	10%		80%	
	44 05 40 05	A \ D A 64 64 64 64	4 - 1						

Optimization of antibodies, selection, protocols and



Lung cancer,


diagnosis and prediction.



Kromogen (farvestof)

Visualiseringssystem (enzymer) Sekundært antistof Primært antistof

Antigen Cellens cytoplasma Cellekerne





Lung cancer,

diagnosis and prediction.



Program

SN ON
ON
014
ON
OIN
МВ
110
МВ
110
receptor
Sit
SN
SN atigen
AVL

Future:

Thursday, September 21 strumab

08:15 - 09:00 45	Optimization of antipodies, selection, protocols and
	controls – breast tumours
09:00 - 09:45 45	Immunohistochemical classification of the
	unknown primary tumour – part I
09:50 - 10:10 20	Coffee
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and
	controls – unknown primary tumours part I
10:45 - 11:30 45	Immunohistochemical classification of the
	unknown primary tumour - partstalc cell
11:35 - 12:05 30	Optimization of antibodies, selection, protocols and

Predictive marker

Tumor Mutational Burden
TMB
SN Micro Satellite Instability
MSI

SN



Lung cancer,

diagnosis and prediction.



Program

Fiogram			,
Wednesday,	Septen	nber 20 th T-cell	
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	
		The technical test approach - pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistoch <mark>emical principles:</mark>	Pre
		The technical test approach - pre-analytical phase II	4116
12:00 - 12:45	45	Immunobistochemical principles:	МВ
		The technical test approach - analytical phase I +	Eva
12:45 - 13:30	45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles:	MB
14:20 - 15:05	45	The technical test approach - analytical phase II	
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	ell receptor
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochemical principles:	
13123 10110		The technical test approach - post analytical phase 11 -	SN antigen
16:15 - 17:00	45	Immunohistochemical classification of breast	
		tumours	AVL
17.00 - 19.00		Social arrangement (optional) - Keglespil (Skittles)	
Thursday, Sep	tembe	r 21 sterolizumab	
08:15 - 09:00	45	Optimization of antipodies, selection, protocols and	CN
		controls – breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the	MV
		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
		controls – unknown primary tumours part I	
10:45 - 11:30	45	Immunohistochemical classification of the	MV
11.25 12.05	20	unknown primary tumour – parkstice cell	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN

Future:

Predictive marker

Evaluation of immune respons

Day 3

Program

Answer

Wednesday, September 20th

. .	-			
09:30 - 10:00		Arrival, coffee		
10:00 - 10:15	15	Welcome and Hitigation with	SN	
10:15 - 11:00	45	Immunohis tpopagion ciples: The technical test approach — pre-analytical phase I	ON	
11:05 - 11:50	45	Immunohistochemical principles:	ON	
12:00 - 12:45	45	The technical test approach - pre-analytical phase II Immunohistal Chief brishled Cell, SCLC The technical test approach - analytical phase I	МВ	
12:45 - 13:30	45	Lunch		
13:30 - 14:15	45	Immunohistochemical principles:	Answer	
14:20 - 15:05 Biopsy	45 _M	The technical test approach - analytical phase II Immunohistochemical principles: Offen Qual test approach Other Gamalignant	SN Day 2	Day 5-8
15:05 - 15.25	20	Coffee		Sunnl
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN	Suppl. Answer
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL	Allower
17.00 - 19.00		tumours Malignant, non smallcell, Skilles (Social arrangement (optional)	D	Molecular analysis
Thursday, Sept	embe	r 21 st		ALK. (ROS. RET)

30

11:35 - 12:05

08:15 - 09:00	45	Optimization of antibodies, selection, protocale no control Subsection with	egreinoma EGFF	1
09:00 - 09:45	45	Immunphistochemical classification of the unknown in the University of the Universit	Answer	Day 3
09:50 - 10:10	20	Coffee and PDI 1analysis		
10:10 - 10:40	30	Coffee and PDL1analysis Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN Day 3	Answer
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	nows carcinoma	

Optimization of antibodies, selection, protocols and



Program

PRELIMINAR

Wednesday, September 20th

		Malignant, Smallcell, SCLC	
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and vintroduction Nothing malignant Day 2 Day 5-8	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach — pre-analytical mase I	ON
11:05 - 11:50	45	Immunohistochemic	ON
		The technical test approach - pre-analytical phase II	ON
12:00 - 12:45	45	Immunohistochemical principles:	MD
		Th Pleurasteffusion tie et Blo	
12:45 - 13:30	45	Luhchedia enusion Cen Dio	
40.00 44.45		_	



The technical test approach - post-analytical phase I 15:05 - 15.25 20 Coffee

Immunohistochemical principles: 15:25 - 16:10 45

The technical test approach - post-analytical phase II

Immunohistochemical classification of breast 16:15 - 17:00 45

Social arrangement (optional) – Keglespil (Skittles) 17.00 - 19.00

Thursday, September 21

08:15 - 09:00	Optimization of antibodies, selection, protocols and
	controls - breast tumours
09:00 - 09:45	5 Ammunohistochemical classification of the
	unknown primary tumour – part I
09:50 - 10:10	0 Coffee
10:10 - 10:40	Optimization of antibodies, selection, protocols and
	controls – unknown primary tumours part I
10:45 - 11:30	5 Immunohistochemical classification of the

MB

SN

PD-L1 (22C3)

11:35 - 12:05

unknown primary tumour – part II Optimization of antibodies, selection, protocols and



11:35 - 12:05

30

Program		PRELIMINAR		
Wednesday, Se	pten	nber 20 th Verification with Immunhisto		
09:30 - 10:00		Arrival, coffee		VEULE SYGENUS
	15	Welcome and introduction Nothing malignant Day 2 Day 5-8	SN	
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach pre-analytical research	ON	
11:05 - 11:50	45	Immunohistochemical test approachis pre-analytical phase II	ON	
12:00 - 12:45	45	Immunohistochemical principles The technical test approach - analytical phase I	МВ	
	45	Lunch EBUS CellBlock		
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	MB	
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN	. 0
15:05 - 15.25	20	Coffee	•	
15:25 - 16:10	35	Immunchistochemical principles: The technical test approach - post analytical phase II	SN	
16:15 - 17:00		Immunohistochemical classification of breast tumours	AVL	
17.00 - 19.00	20	Social arrangement (optional) – Keglespil (<u>Skittles</u>)	4	001
Thursday, Septer	mbe	r 21 st		
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls - breast turnours	SN	
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part 1	MV	
	20	Coffee		
10:10 - 10:40	30 CK5	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN	
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV	A CONTRACTOR OF THE PARTY OF TH
44 05 40 05			_	

Optimization of antibodies, selection, protocols and

_{SN}PD-L1 (22C3)



Program	PRELIMINAR	
Wednesday, Sep		
09:30 - 10:00	Arrival, coffee	VEULE SYGENUS
10:00 - 10:15 1	, and the second	SN
10:15 - 11:00 4	Immunohistochemical principles: The technical test approach pre-analytical approach pre-analytical approach pre-analytical approach.	ON
11:05 - 11:50 4	A de	ON
12:00 - 12:45 4		МВ
12:45 - 13:30 4		
13:30 - 14:15 4	Immunohistochemical principles: The technical test approach - analytical phase II	МВ
14:20 - 15:05	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN
15:05 - 15.25	Coffee	
15:25 - 16:10	Lomunohistochemical principles: The technical test approach - post-analytical phase II	SN
16:15 - 17	Immunohistochemical classification of breast tumours	AVL
17.00 – 19.00.	Social arrangement (optional) – Keglespil (<u>Skittles</u>)	The state of the s
Thursday, Septem	ber 21 st	
08:15 - 09:00	Optimization of antibodies, selection, protocols and controls - breast tumours	SN
09:00 - 09:45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10	Coffee	
10:10 - 10:40	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30 C4	5/6Iក្កក្រប្រក្នុងស្រុនtochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05 3	, , , , , , , , , , , , , , , , , , ,	PD-L1 (22C3)


Malignant, smallcell, SCLC

Program

PRELIMINAR

Wednesday, September 20th

Waighart, Shaildeir, GOLO
Arrival, coffee
Welcome and introduction Nothing malignant Day 2 Day 5-8 SN
Immunohistochemical principles: Malignanat gon-smalleell NCSI C
The technical test approach - pre-analy test approach
Immunohistochemical proprietables: Answer Day 3 ON
The technical test approachs pre-analytical phase II
Immunohistochemical principles:
The technical test approach - analytical phase I
Lunch Coarse needle blopsy
Immunohistochemical principles:



he technical test approach - post-analytical phase II nunohistochemical classification of breast 16:15 - 17:00


17.00 - 19.00arrangement (optional) - Keglespil (Skittles)

Thursday, Sept

08:15 - 09:00	45	Optimization of antibodies, selection, protocols and
09:00 - 09:45	E 9	controls – breast tumours Immunohistochemical classification of the
120 E 91		unknown primary tumour – part I
	20	Coffee
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and
188		controls – unknown primary tumours part I
10:45 - 11:30	45	Immunohistochemical classification of the
		unknown primary tumour – part II
11:3 tf 1 <u>an</u> @CK7+ ;	30	Optimization of antibodies, selection, protocols and

Optimization of antibodies, selection, protocols and





Nord**iQC**

The Diagnostic algorithm


Program

PRELIMINAR

Wednesday, September 20th

- -	_	Malignant, smallcell, SCLC	
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction Nothing malignant Day 2 Day 5-8	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach pre-analytical presse I	ON
11:05 - 11:50	45	Immunohistochemica proprinciples:	ON
		The technical test approach pre-analytical phase II	ON
12:00 - 12:45	45	Immunohistochemical principles:	MD
		The technical test approach - analytical phase I	MB
12:45 - 13:30	45	Lunch Coarse needle biopsy	V
13:30 - 14:15	45	Immunohistochemical principles:	/





controls – unknown primary tumours part I

10:45 – 11:30

45
Immunohistochemical classification of the unknown primary tumour – part II

11:351 and CK7+

30
Optimization of antibodies, selection, protocols and

MV PDL1 (22C3)

136

_

The Diagnostic algorithm

Program

PRELIMINAR


Wednesday, September 20th

		Malignant, smallcell, SCLC
09:30 - 10:00		Arrival, coffee
10:00 - 10:15	15	Welcome and introduction Nothing malignant Day 2 Day 5-8
10:15 - 11:00	45	Immunohistochemical principles:
		The technical test approach — pre-analytical approach
11:05 - 11:50	45	Immunohistochemica Log Politicipies Answer Day 3
		The technical test approachs pre-analytical phase II
12:00 - 12:45	45	Immunohistochemical principles:
		The technical test approach - analytical phase I



MB

ON



unknown primary tumour - part I


10:10 – 10:40

20 Coffee Optimization of antibodies, selection, protocols and CN

20 Coffee Optimization of antibodies, selection, protocols and CN

137

Patient selection in lung cancer: Evolution over time





Lung cancer,

diagnosis and prediction.



Program

Wednesday September 20th research landscape – 09:30 - 10:00 Arrival, coffee 10:00 - 10:15 O A 15 r Welcome and introduction SN 10:15 - 11:00 Immunohistochemical principles: ON The technical test approach - pre-analytic Immunohistochemnical principles! 11:05 - 11:50 Cancer Stron Cell Targeting (PPAR, Hedgeho The technical test approach, 734 pre analytical phase 1. 12:00 - 12:45 Immunohistochemical principles 45 Vascular Disrupting Ager The technical test approach - analytical phase 12:45 - 13:30 13:30 - 14:150 = salc Immuno<mark>histochemical phinciples</mark> ①_{= TKI} The technical test approach analytical phase 14:20 - 15:05^{(A) = Antibody} 45 Immunohisto demical principles: **DNA Repair Inhibitors** The technical test approach Apost analytical phase 15:05 - 15.25 EGF: Whibitors Offe Canitumumab BIBW2992 Bevacizumab A 15:25 - 16:10 45 Immunohistochemical principles The technical test approach proof analytical phase I Src Inhibitors mmunchistochemical dassification of breast 16:15 - 17:00 TK1258 F-50035 17.00 - 19.00Social arrangement (optional) - Keglesbil (Sk Thursday, September 21 **** zation of antipodies selection, protocols and 08:15 - 09:00 controls - breast tumours ABT-2030 AGIufosfamid 09:00 - 09:45 45 Immunohistochemical classification of the mmunostimulants/Vaccine un protein Describition y tumour - part 15-1411 09:50 - 10:10 20 Coffee Antimetabolites 30 Neeta Soma Optimization of antibodies, selection, protocols and 10:10 - 10:40 SN controls - unknown primary tumours part I Immunohistochemical classification of the 10:45 - 11:30 45 MV unknown primary tumour - part II 11:35 - 12:05 30 Optimization of antibodies, selection, protocols and SN